l v ng con r asts annual report value innovationboehringer ingelheim group financial highlights amounts millions eur unless otherwise indicated change net sales region europe americas asia australia africa business prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales research development personnel costs average number employees operating income operating income net sales income taxes income taxes net sales shareholders equity return shareholders equity cash flow investments tangible assets depreciation tangible assets top products prescription medicines top products consumer health care net sales millions eur change net sales millions eur change spiriva buscopan pradaxa dulcolax micardis mucosolvan combivent pharmaton content company product portfolio shareholders perspective branded prescription medicines key aspects respiratory diseases corporate bodies cardiovascular diseases highlights medicine metabolic diseases oncology living contrasts diseases central nervous system infectious diseases safety challenge commitment performance consumer health care individuality standards cough cold chance strategy sore throat pain group management report gastrointestinal diseases information group companies vitamins supplements report economic position leg vein health report postbalance sheet date events urological diseases report opportunities risks report expected developments animal health food producing animals swine consolidated food producing animals poultry financial statements food producing animals cattle overview major companion animals horse consolidated companies companion animals small animals consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements auditors report safety challenge p tnetnoc commitment performance p individuality standards p chance strategy p company boehringer ingelheim group one worlds leading pharmaceutical companies headquartered ingelheim germany boehringer ingelheim operates globally affiliates total employees focus familyowned company founded researching developing manu facturing marketing new medications high therapeutic value human veterinary medicine social responsibility important element corporate culture boehringer ingelheim includes worldwide involvement social projects initiative making health caring employees respect equal opportunities reconciliation work family life form foundation mutual cooperation every thing company focuses environmental protection sustainability innovative caring responsible independent annual report boehringer ingelheim shareholders perspective christian boehringer chairman shareholders committee shareholders perspective familyowned researchdriven pharmaceutical company boehringer ingelheim many years adhered vision value innovation principle guides actions aim provide patients worldwide beneficial medicines safeguard boehringer ingelheims independence innovation care responsibility independence way work together achieve goals determines daytoday business company however fields tension vital reconcile differing interests heading living contrasts annual report includes examples boehringer ingelheim succeeds maintaining balance differences years company founded albert boehringer respect diversity thus contrasts ever consciously aware changes take place inside outside company understand draw right conclusions possible us remain competitive globally important look issues different viewpoints order continue meet differing needs patients complex environment annual report shows different approaches standpoints talents taking company forward makes boehringer ingelheim stand ability balance contrasts identify differences also systematically take advantage opportunities companys employees individuality different experiences creativity foundation success annual report however also show areas within company little room diversity terms drug safety surveillance example absolutely essential adhere strictly prescribed procedures regulations reason one main concerns find right balance individuality one hand narrowly defined standards annual report boehringer ingelheim shareholders perspective possible variety ways market medicines convincing benefits acceptable risks marketing medicine completely free side effects challenge researchdriven pharmaceutical companies impossible meet present time reason closely support launch new medicines detailed studies using data patients general clinical practice epidemiology continuing pursue phase iii clinical trials new trials patients phase iv key question us identify risks early stage possibly appear medicines administered hundreds thousands patients suffer various secondary diseases also taking several different medicines ensure risks minimised patients wellbeing main concern shareholders support boehringer ingelheim researchdriven pharmaceutical company focussing indications expected achieve high volume sales also developing medicines people rare diseases idiopathic pulmonary fibrosis ipf possible powerful business performance longterm focus since enables us invest research development thus ensures continue provide portfolio medicines meet needs many patients future independence familyowned company firmly anchored corporate culture ensure remains boehringer ingelheim pursues distinct strategy also terms research moreover important identify opportunities sometimes arise chance take full advantage actively promoting innovation means among things living contrasts time focus joint strengths values successful despite many challenges face case company also demonstrate strengths future rapidly changing market environment challenge taken employees every day board managing directors deserve sincere thanks outstanding efforts passion able bring many activities favourable conclusion priority current year launch new medicines look forward therefore ebbs flows business c hallenges successes lie ahead signed christian boehringer chairman shareholders committee annual report boehringer ingelheim kkeeyy aassppeeccttss andreas barner wolfgang baiker allan hillgrove joachim hasenmaier hubertus von baumbach left right board managing directors key aspects looking back financial year ended stands significant progress medicinal developments succeeded submitting wide range medicines regulatory authorities marketing approval launching market initial countries medicines represent highly innovative therapeutic alternatives case ofev finally offer new options patients lifethreatening idiopathic pulmonary fibrosis physicians treating hand intense year us year faced many business challenges guiding principle times create sufficient space future able continue invest organic sustainable growth goal remain competitive independent new medicines important prerequisite future success respect exceptionally good year list new products long jardiance treatment type diabetes vargatef advanced lung cancer following chemotherapy ofev treatment rare disease idiopathic pulmonary fibrosis ipf striverdi respimat patients chronic obstructive pulmonary disease copd furthermore made established medicines available wider group patients received marketing authorisation europe spiriva respimat asthma patients receiving standard treatment still exhibit symptoms pradaxa prevention treatment deepvein thrombosis pulmonary embolism addition submitted large number additional marketing authorisation applications new medicines indications include new copd therapy tiotropiumolodaterol respimat combination product empagliflozin metformin addition combination tablet empagliflozin linagliptin treatment type diabetes made excellent progress development late pipeline example development medication shortest time cancels effect anticoagulant pradaxa first quarter submitted reversal agent marketing approval regulatory authorities usa europe also working new treatment options alzheimers disease schizophrenia psychiatric disorders therapeutic area immu nology pipeline portfolio includes projects severe psoriasis spondylarthritis inflammatory disease joints crohns disease chronic inflammatory bowel disease annual report boehringer ingelheim key aspects currently working total research projects indication important research work future medicines us also seen research development expenditure amounted billion euros representing per cent total sales people worldwide employed rd boehringer ingelheim also used bring number challenges faced past years favourable conclusion important milestones lifting warning letter issued us food drug administration fda manufacturing facility ingelheim germany sale us subsidiary ben venue laboratories inc settlement achieved us litigation regarding pradaxa independent analysis conducted fda towards end last year based data obtained patients suffering atrial fibrillation confirmed positive safety efficacy profile pradaxa daily practice innovation basis longterm sustained growth boehringer ingelheim highly successful last year nevertheless market environment became difficult whole pharmaceutical industry thus also us particularly usa important market us cause one hand severe cuts due reforms healthcare system hand consolidation insurance industry impact net sales prescription medicines important business generated total net sales amounting million euros bestselling products continued respiratory medicine spiriva anti coagulant pradaxa micardis treatment high blood pressure overall accumulated around million patient years experience medicines aforementioned challenges continue occupy us therefore begun early adjustment global cost structure follows need save thus launched programmes important markets order maintain competitiveness example aim gain space growth innovation order also operate successfully market future operating income million euros return net sales per cent right way short term schedule planned product launches form basis future growth long term new research strategy focusing four research areas immunology respiratory diseases oncology cardiometabolic diseases diseases central nervous system taken steps ensure able develop innovative products end important sound new avenues research forward looking technologies early stage annual report boehringer ingelheim key aspects current financial year set goal thanks little way large number launches achieving increase net sales compared previous year continue work intensively ensure many patients possible supplied medicines time raise competitiveness intense demanding phase employees deserve appreciation would like thank sincerely extraordinary efforts face difficult overall conditions demonstrated great willingness assume responsibility flexibility personal initiative success depended great commitment depend current financial year well signed signed andreas barner wolfgang baiker signed signed hubertus von baumbach joachim hasenmaier signed allan hillgrove corporate bodies shareholders committee board managing directors christian boehringer prof dr dr andreas barner chairman shareholders committee chairman board corporate board divisions human resources research christoph boehringer development medicine erich von baumbach jr dr wolfgang baiker corporate board divisions operations isabel boehringer biopharmaceuticals dr mathias boehringer hubertus von baumbach corporate board division finance dr joachim hasenmaier advisory board corporate board divisions animal health consumer health care egbert appel trustee martin hilti family trust allan hillgrove president hilti foundation corporate board division chairman advisory board pharma marketing sales kurt beck former ministerpresident dr andreas kreimeyer member board executive directors research executive director basf se jan rinnert chairman board management heraeus holding gmbh republic austria annual report boehringer ingelheim highlights medicine news therapeutic areas research development medicine boehringer ingelheim look back yet another successful year research development medicine boehringer applications market authorisation european ingelheim look back outstanding successful year union eu usa additionally boehringer ingelheim registrations launches concerned submitted application market authorisation usa medicine treatment type diabetes combination company received approval various markets tablet consisting empagliflozin linagliptin empagliflozin jardiance diabetes nintedanib vargatef approved early treatment advanced adenocarcinoma lung failure initial chemotherapy olodaterol striverdi field cardiovascular disease boehringer ingelheim respimat treatment chronic obstructive pulmonary making progress development antidote disease copd additionally authorities granted reg istration anticoagulant pradaxa furthermore three new clinical extension tiotropium spiriva respimat asthma studies currently investigating pradaxa improve patients remain symptomatic standard therapy treatment patients risk stroke addition two real dabigatran pradaxa received registration secondary world studies investigating use pradaxa everyday prevention treatment acute deep vein thrombosis clinical practice help inform physicians patients daily pulmonary embolism furthermore spiriva respimat decisionm aking copd nintedanib ofev idiopathic pulmonary fibrosis ipf received approval usa music future currently loudest two therapeutic areas boehringer ingelheim research devel even future launches sight preparations opment treatment diseases central nervous running full speed field respiratory diseases system cns progressing boehringer ingelheim boehringer ingelheim already applied regulatory approval working solutions schizophrenia alzheimers disease fixeddose combination spiriva tiotropium among others therapeutic area immunology striverdi olodaterol respimat treatment copd meanwhile established meaningful pipeline portfolio including europe usa expects market authorisation advanced projects psoriasis spondyloarthritis inflam new diabetes drug combination product matory disease spine crohns disease chronic empagliflozin metformin company also submitted inflammatory bowel disease r espiratory diseases leadership respiratory alveole leader respiratory regulatory approval requested medicines years boehringer europe usa expected ingelheim continued develop oxygen bloodstream boehringer innovative new products provide ingelheim developed ofev nintedanib meaningful medical benefit patients every second asthma patient still treatment patients ipf copd debilitating lifethreatening suffers symptoms despite current designated breakthrough therapy disease affects million standard medication spiriva enabling approval usa early patients worldwide spiriva tiotropium respimat company offering first october european medicines agency prescribed maintenance new class inhaled asthma treatments ema approved ofev january therapy backbone portfolio decade spiriva respimat accelerated approval assessment complemented specifically de approved many countries addon earlier relevant committee medic signed combination partner striverdi therapy symptomatic adult asthma inal products human use chmp olodaterol respimat combining patients published positive opinion nintedanib substances single respimat ipf inhaler fixeddose combination idiopathic pulmonary fibrosis ipf n europe spiriva respimat asthma indicated potential offer even greater benefits rare severely debilitating fatal lung addon maintenance bronchodilator treatment adult patients currently treated patients improvement lung disease characterised progres maintenance combination inhaled corticosteroids function leads relief breath sive scarring lung tissue lungs g budesonideday equivalent long acting agonists experienced one lessness improved quality life lose ability take transfer severe exacerbations previous year oncology progress made new cancer treatments boehringer ingelheim longterm nintedanib vargatef approved commitment delivering novel cancer end european therapies high therapeutic value medicines agency ema treatment patients successfully advanced patients advanced adenocarcinoma oncology franchise aiming provide lung failure initial chemo new treatment options patients therapy approval among vargatef works inhibiting growth new blood vessels depriving solid tumours grounds based promising patient tumour nutrients required growth survival data nintedanib combina spread giotrifgilotrif afatinib approved tion docetaxel indication countries worldwide boehringer ingelheim continues efforts patients distinct type non make treatment available globally small cell lung cancer new analyses phase iii trials tumour types adds current portfolio show promising results terms patient ongoing approved compounds boehringer ingelheim expanded lung survival afatinib compared cancer development portfolio standard chemotherapy growing pipeline oncology com major inlicensing deal novel thera pounds various stages development peutic vaccine annual report boehringer ingelheim highlights medicine cardiovascular diseases ongoing innovation cardiovascular boehringer ingelheims oral anticoagulant physicians idarucizumab already demon pradaxa dabigatran etexilate prevent strated potential immediate complete sus lifethreatening blood clots may cause harm tained reversal anticoagulant effect patients approved seven medical uses pradaxa studies healthy volunteers since many countries worldwide pradaxa mid reversead global patient study received new approvals treatment preven underway investigate reversal agent tion recurrence deep vein thrombosis dvt clinical setting patients taking pradaxa pulmonary embolism pe numerous countries require rapid reversal anticoagulant effect worldwide including usa europe emergency situation company continues look ways three new clinical studies respect esus improve care patients risk blood clots redual pci recircuit currently new studies pradaxa investiga ting pradaxa improve treatment development idarucizumab reversal agent patients risk stroke gloriaaf anticoagulant effect pradaxa recovery dvtpe realworld studies investigating use pradaxa help inform demanding development reversal agent physicians patients decisionmaking every pradaxa part commitment broaden day clinical practice existing range emergency management options dabigatran reversal agent metabolism commitment diabetes type diabetes complex condition diabetes jardiance empagliflozin blood sugar weight loss two new treatments required second diabetes medication years improvements systolic blood patients physicians help control trajenta linagliptin approved pressure glimepiride associated blood glucose levels boehringer several countries first launches increase body weight ingelheim made significant progress occurred jardiance systolic blood pressure terms regula bringing new treatment options people trajenta part alliance tory filings combination product eli lilly company large cardiovas empagliflozin metformin immediate cular outcome trials products release submitted schedule complete time eu usa combination tablet results jardiance trial empa empagliflozin linagliptin reg outcome expected submitted usa approved early jardiance lowers blood glucose levels people diabetes removing addition growing diabetes excess blood glucose body via portfolio new insulin glargine product urine compared glimepiride part alliance eli commonly used treatment improve lilly approved first biosimilar pancreas islets langerhans blood sugar control empagliflozin led insulin eu received tentative statistically significant reduction approval usa diseases central nervous system new limelight central nervous system diseases company mainly known suffering substantial impairment innovative treatment approaches many parkinson medicine sifrol boehringer cognitive functions including learn socalled neuropsychiatric disorders ingelheims cns pipeline may reveal ing memory problems surprise different compounds poten common schizophrenia alzheimers boehringer ingelheims way forward tially treat cns diseases develop disease two indications phase ii cns also includes research activity ment may good news patients clinical testing already running fields psychiatry including treat clinical phase several com mentresistant depression pounds follow soon explores beyond pill approaches benefit patients expected cognitive impairment problem complementing medication many psychiatric indications related approaches drug therapy may symptoms may appear across many cns example combined cognitive diseases deciphering brain circuitries remediation mental training helps cognition underlying mechanism concentration attention memory actions human brain approach holistically offers mandate cns discovery research best option individually aim finally develop effective optimised treatment nerve cell annual report boehringer ingelheim highlights medicine immunology fastgrowing therapeutic area immunology boehringer ingelheims immunology portfolio therapeutic strategies clinic boehringer grown substantially recent times ingelheim indication psoriasis may broad range immunological diseases central first boehringer ingelheims frontrunner interest eg autoimmune disease family spondy molecule bi show advanced clinical data loarthritis one form also known spondyloarthritis crohns disease possibly morbus bechterew ankylosing spondylitis follow year phase ii study results disease causes arthritis associated pain stiff ness often spine joints onset apart bi additional compound disease per cent earlier clinical stages development already persons western societies suffer occurs typically demonstrated high therapeutic potential patients late adolescence early adulthood rare suffering immunological diseases ankylosing spondylitis begin age ano ther autoimmune disease crohns disease chronic inflammatory bowel disease affects part gastrointestinal tract resulting pain abdomen serious symptoms crohns disease affects people per europe north america incidence increasing mechanism bodys immune response certain trigger scientifically stood corresponding physiologic pathologic effects investigated common evaluate one compound potential effects several diseases associated immunological pathway since discovery called il immune pathway decade ago immunologists clinicians diligently worked bring novel antibodies b cells psoriasis skin cells need find better therapies immunology take psoriasis develops immune boehringer ingelheims advanced compound bi system mistakenly attacks inflames destroys healthy frontrunner molecule humanised antibody body tissue may cause red scaly patches often itchy blocks il pathway consequently prevents binding painful body psoriasis often highly troublesome signalling il receptor results feeling shame unwil lingness mingle p eople solitude depression thus making lives promising interim clinical study results phase ii patients miserable study included patients moderate severe psoriasis presented american academy dermatology understanding psoriasis advanced recent annual meeting aad primary endpoint analysis week years point longer considered cosme showed unexpectedly high response rate bi tic problem unpleasant skin condition rather un nearly doubled percentage patients achieving least derstood chronic systemic immunemediated disease almost clear skin pasi status compared active affects four per cent western populations comparator study biologic ustekinumab efficacious ages third patients moderate severe psoria sis therapy approved indication approximately per plaque psoriasis common form affecting cent patients reached least almost clear skin per cent psoriasis patients third patients weeks two doses substance pasi clinical additionally suffering joint disease strong score determine severity extent skin involvement link diabetes heart disease depression psoriasis researchers made substantial progress deciphering results still confirmed trial pathways behind range immunological diseases data including respective phase iii results medical com substantial scientific steps forward made past years munity aad considered results exceptional example interleukin il physiological pathw ay activates emerged key driver chronic flammatory process psoriasis immunolog ical diseases aannnnuuaall rreeppoorrtt bbooeehhrriinnggeerr iinnggeellhheeiimm living contrasts caring living contrasts safety challenge commitment performance individuality standards chance strategy familyowned researchdriven pharmaceutical company boehringer ingelheim operates field tension various goals values precisely balance safety challenge commitment performance individuality standards least chance strategy decisive companys success want manufacture medicines highest possible safety standards p cant take granted pharmaceutical companies develop medicines rare disease ipf p want create corporate culture aware differences truly appreciates respects p lbert boehringers attitude guides us day recognise opportunities utilise p living contrasts caring living contrasts safety challenge commitment performance individuality standards chance strategy familyowned researchdriven pharmaceutical company boehringer ingelheim operates field tension various goals values precisely balance safety challenge commitment performance individuality standards least chance strategy decisive companys success monitor every step use medicines medicine dispensed patients took dosage health outcomes p im proud bringing innovative treatments patients high need also feel passion team members p public health reason see standards absolutely indispensable p research new biological entities extremely targeted good strategy planning help identify opportunities focus increase probability success p innovative sa f ety chal l enge yuka nagashima narita japan age quality manager collaborates closely colleagues boehringer ingelheim supply ever better safer products prof sebastian schneeweiss age physician professor medicine pharmacoepidemiology harvard medical school boston usa researches medical records tens thousands patients guarantee safety medicines ongoing challenge annual report boehringer ingelheim living contrasts innovative want manufacture medicines highest possible safety standards everything safety innovation among things means watertight include painkiller eve hythiol cplus laxative packages easytoopen blister packs package leaflets surulac whenever colleagues discover easy read ideas kind yuka nagashima thing could affect quality contacts teams quality manager production facility narita japan involved suggests alternatives minor signs could lead making medicines even safer problem picked immediately recently nagashima face new challenge comes packaging nagashima sits marketing department came new packaging colleagues development regulatory packaging idea became clear possibly makes lettering relevant functions together develop customer packaging difficult read nagashima friendly format quality manager currently working colleagues came marketing asked us increase staff development new packaging designed tractiveness packaging patients well enhancing ensure medicines longer shelf life achieve readability recalls objective experimenting materials exhibit extremely low moisture permeability nagashima quality manager ssp narita plant east tokyo ssp co ltd leads consumer health care chc nagashima coordinates work carried business boehringer ingelheim japan core task various departments means communicates closely team colleagues secure quality raw materials result spends almost third working day packaging materials bulk final products cross functional communication uses another per cent innovation needs safety challenge pharmacoepidemiologists boehringer ingelheim take care employment real world data say everyday clinical data order obtain already clinical development precise understanding patients treated well investigate safety efficacy medicines launched market example test longterm studies whether side effects occur patients studies cooperate worldwide renowned scientists professor samy suissa professor sebastian schneeweiss wellpractised procedures product discus sing topics identified mem bers team also keeps contact colleagues countries learn advanced new medications analytical methods share learnings order guarantee boehringer ingelheim successfully expanded product port folio best possible product quality finding better pharmaceutical company brought three new innovative solutions prescription medicines market ofev treatment idiopathic pulmonary fibrosis ipf jardiance quality operation department treatment adults type diabetes striverdi achieves thanks adherence wellpractised olodaterol respimat longterm treatment patients procedures product nothing leaves chronic obstructive pulmonary disease copd plant narita unless nagashimas team given approval work performs vital safety medicines devil often detail prepared every eventuality set challenging goal want manufacture medicines highest possible safety standards jardiance ofev striverdi annual report boehringer ingelheim living contrasts innovative monitor every step use medicines medicine dispensed patients took dosage health outcomes investigating uncertainty clinical trials required market authorisation particularly case new medicines doctors new medicine rarely case possible effects access clinical trial results despite lack identified reason therefore pharmaco certainty sometimes make decisions within minutes epidemiologists sebastian schneeweiss investigate hours matter life death prescribing unknown undesired pharmacological effects doctors weigh differences observe terview harvard clinical research scientist explains individual patient statistical findings research important aspects scientists gathered clinical trials often say jokingly somewhat admiringly doctors heroes generalising professor schneeweiss newly authorised medicines safe statistically derived knowledge individual patients thats colleagues come research yes course theyre safe extent previously unknown side effects occur practice proven clinical trials however nature way increase statistical knowledge gained limited validity average patients clinical trials involved clinical trial patients thought representative majority population never exactly analyse tens thousands electronically possible carry tests every conceivable type stored medical histories patients prescribed patient way newly authorised medicine appears new medicine result analyses able identify market therefore possible specific rare side effects much higher degree probability type patient tested possible clinical trials also identify desired effects patient subgroups doctors allow luxury high degree uncertainty prescribing new medicines data come shortly marketing choice electronic medical records example use dont want miss benefits come new products doctors notes electronic bills send health insurance sebastian schneeweiss office boston usa pharma coepidemiologists experts medicine also trained epide miology biostatistics companies enables us look step process means reporting system side effects known phar medicine dispensed patients macovigilance carrying systematic studies took medicine dosage health following market authorisation latter area boehringer comes data deidentified ensure ingelheim works closely high calibre scientific institutions trace back information individual persons worldwide group pharmacoepidemiologists unfortunately still far experts field find whether patient suffering side whole pharmaceutical companies effect compare medication use data results medical examinations obtained hospitals check genuine problem finding welltrained people variety things increase number experts medicine also qualified patients taken new medicine admitted fields epidemiology biostatistics youve hospital stroke pulmonary embolism completed studies position indication severe side effects immediately reliably collect analyse interpret epidemiological data look matter thats important part job drug use effects training programmes long identifying potentially dangerous side effects interactions expensive harvard medical school accept three doc clinical trials revealed also equally im toral masters students year portant doctor patient confirm handful comparable programmes worldwide side effects manufacturers help make medicines even safer pharmaceutical companies must ensure read subject pharmacovigilance interview high priority given identifying possible side effects dr christopher corsico global head clinical development soon possible launching product onto market medicine regulatory boehringer ingelheim annual report boehringer ingelheim caring ashley hulme age ferndown dorset uk retired electrical engineer people rare diseases commitment researchdriven pharmaceutical companies highly significant performance deliver decisively improve patients situation c ommitment pe rformance andrea sambatti global team leader ipf marketing ingelheim germany age boehringer ingelheim delivers strong business performance enabling us commit patients rare diseases annual report boehringer ingelheim living contrasts caring cant take granted pharmaceutical companies develop medicines rare disease ipf renewed zest life englishman ashley hulme suffers rare disease treatment turned extremely difficult year idiopathic pulmonary fibrosis ipf nevertheless tries old recalls little clearly presented information live normal life possible available cause disease also still unknown information provided many specialist websites towards end became clear ashley difficult patients understand others give com something wrong increasing frequency electrical pletely false impression disease searching internet engineer little town ferndown south initially made one thing become blatantly clear ipf england felt strangely short breath speaking large extremely rare according current estimates group people physical exertion never cases per population worldwide germany ex perienced anything like ashleys wife jenny urged approximately ipf patients usa husband see doctor subsequently carried around people develop ipf suffer shortness lung function test took xray ashleys chest breath coughing quality life severely impaired ferred specialist nearby town poole often difficulties everyday things high resolution computerised tomography ct scan revealed going long walks housework gardening reason distress suffering idiopathic advanced stages disease even walking stairs difficult pulmonary fibrosis ipf explained doctor rare condition causes progressive scarring lung tissue diagnosis ipf hit entire family hard ashley cases leads patients death within years wife children live close parents biggest shock however learning limited life back home ferndown ashley sat computer expectancy still cure ipf says ashley half began looking information ipf possible forms patients die devastating disease within two despite serious illness ashley hulme convinced situation relatively good im typical case says three years diagnosis ashley family however ipf patients quickly obtained access decided going fight engineer always special ipf medicine addition members family zest life active lifestyle still lots determined fight disease together support plans included activities grandchildren trips ashley wife jenny continue live abroad wife normal life possible success already planning spend next holiday germany confidence increased result fact medicines available alleviate suffering since ashley hulme received reimbursement time effort required input annual report beginning ashley taking medicine usbased pharmaceutical company ofev based active ingredient nintedanib boehringer ingelheim impact ipf lung launched ipf medicine market usa beginning launch number european countries means researchdriven pharmaceutical company normal ipf offer patients new therapy option regulatory authorities worldwide currently examining applications marketing resultant scarring honeycombing authorisation lung restricts breathing oxygen exchange despite severe illness ashley convinced situation relatively good typical case says condition diagnosed much faster case annual report boehringer ingelheim living contrasts caring right thing right way marketing specialist heads global marketing team prepares ofev launch andrea sambatti works boehringer ingelheims global headquarters ingelheim germany andrea sambatti leading global launch new shown promising results nintedanib ipf treatment medicine ofev offers new hope patients job would head global marketing team pre idiopathic pulmonary fibrosis ipf pare product launch saw great unique professional challenge also personal opportunity graduating university andrea sambatti exposed different culture gain international experience intended work pharma ceutical industry recalls relocated husband worked several years automotive industry two sons germany production engineer enrolled mba marketing met number people working pharmaceutical companies years sambattis arrival nintedanib shown fascinated recalls brazilian originally comes effective ipf treatment two identical phase iii trials area near paulo exactly wanted nintedanib slows disease progression reducing decline exciting dynamic industry offered lung function per cent also reduces risk sudden opportunity positive impact peoples lives severe worsening disease called acute ipf exacer bations exacerbations associated dramatic last years sambatti working different decline lung function fatal ofev conven areas pharmaceutical companies including primary ient oral medication patients take two capsules specialty care increasing expertise sales marketing day leadership positions joined boehringer ingelheim appointed business unit head oncology working closely team extended multi brazil aware special atmosphere disciplinary teams well colleagues familyowned business longterm vision boehringer world sambatti spent last years preparing ingelheim especially committed wellbeing patients launch nintedanib brand name ofev shortly receiving food drug administration approval october full year new job invited work ofev became commercially available one corporate headquarters ingelheim germany phase ii trials committed rare diseases im proud bringing innovative treatments patients high need also feel passion team members interview dr christian schilling head therapeutic areas boehringer ingelheim first pharmaceutical treatments ipf patients commitment research rare diseases conflict usa approved europe january pressure develop new medicine pays way healthcare payers also expect price medicine higher people suffer boehringer ingelheim sees strategic fit disease addition develop new modes ofev within respiratory portfolio bringing action several indications thereby opportunity new treatment ofev patients several indications contribute towards recouping invest significant unmet medical need ments research result many years research demonstrates commitment making difference pa boehringer ingelheim committed helping people tients respiratory diseases signific ant rare diseases first place commercial opportunity explains sambatti many years corporate vision value innovation guiding principle align research proud ofev support thou commit areas see major unmet sands ipf patients families deal therapeutic need required knowhow rare fatal disease usa support research development include several quite rare launch boehringer ingelheim established diseases naturally also take commercial aspects account open doors comprehensive patient support conflict interests programme provides broad range financial ul timately achieve perceptible therapeutic progress also nursing support services want patients financial success given best possible treatment says sambatti moved furthermore researchdriven pharmaceutical company pharmaceutical industry specifically year corporate history also see boehringer ingelheim part healthcare system want make contribution therapeutic progress even profitable per se aannnnuuaall rreeppoorrtt bbooeehhrriinnggeerr iinnggeellhheeiimm responsible age biberach der riss germany denise hottmann manager diversity inclusion germany high degree individuality team generates new ideas works however members comply common standards individuality standard ingelheim germany dr christopher corsico age global head clinical development medicine regulatory without standards difficult comply strict regulations governing pharmaceutical industry limited flexibility available individuality guaranteeing safety medicines wellbeing patients annual report boehringer ingelheim living contrasts responsible mutual respect brings strengths cube represents variety topics related diversity inclusion talent management life balance leadership culture denise hottmann shows socalled cube perspectives developed boehringer ingelheim diversity inclusion manager denise hottmann developing company employees hottmann explains together corporate culture employees colleagues human resources pay careful attention example wording job advertisements also ask denise hottmann diversity inclusion offer workshops various departments means emphasises appreciating prepare diversity strategies also enable differences therefore definition diversity inclusion managers develop clearer understanding culture boehringer ingelheim purposefully kept broad values differences hottmann likes put choos explains diversity represents differences similarities ing members team example one ask people regarding gender culture ethnicity oneself question see someone troublemaker education religion dimensions often resulting whos likely put forward opinion thats completely diversity perspectives dif ferent others someone really want listen im interested real alternatives hottmann graduate international management diversity inclusion manager boehringer ingelheim according current research diversity kind germany heading special centre expertise social charity project contributes companys since important aspect job keep success begin diversity enables company maintain right balance individuality standards access markets want help people ill precisely maintain balance personal brazil asia know need multicultural strengths needs individual one hand teams help situations says hottmann common goals values company secondly diversity makes boehringer ingelheim diversity inclusion means must make attractive employer remain successful also need conscious effort manage diversity order add value future powerful multigenerational workforce prepared standards individuality complementary per cent women almost half boehringer ingelheims employees women germany example among top executives want create corporate female share amounts per cent total management per cent women furthermore workforce highly culture aware international people countries work head differences truly appreciates quarters ingelheim employees germany respects years old trend rising boehringer ingelheim germany employs people disabilities engage lifelong learning explains hottmann reason company places high value boehringer ingelheim men group continuous training members women workforce also employees later stages career thirdly diversified teams members able contribute differences side effect notifications frequently come better solutions diversity expert adds thats want create received month average boehringer ingelheims phar corporate culture aware differences macovigilance department concerning products truly appreciates respects marketed developed company submitted health authorities worldwide physicians test token however everyone must analyse information potential side effects initiate comply common standards ensure pul measures order ensure optimal riskbenefit profile ling direction respect exam boehringer ingelheim products well continuously inform ple laidback manner may used patients prescribers current state knowledge excuse avoid getting involved focus corporate values hottmann convinced diversity lead success side effect physicians test notifications analysis aannnnuuaall rreeppoorrtt bbooeehhrriinnggeerr iinnggeellhheeiimm living contrasts responsible standards wellbeing patients public health reason see standards absolutely indispensable dr christopher corsico global head clinical development standards important factor phases pharma medicine regulatory boehringer ingelheim respon ceutical drug development beginning research sible among things drug safety surveillance otherwise development medicine finally approved known pharmacovigilance people employed completion extensive trials work far group worldwide systematically monitor adverse side effects must systematically analyse experience patients health store data large database fixed reporting care prescribers medicines use infor standards essential ensure benefit patients mation update package leaflets communicate currently data systematically collected information available scientific information products lost obtain information theres way knowing dr corsico work strictly regulated industry uses medicines regulations constantly becoming stringent mem bers staff required implement directives comprehensive pharmacovigilance system letter much freedom express utilises standardised systematic procedures collect individuality analyse side effect data reported us company employees doctors patients family members health authorities many areas company individuality reported scientific literature news media creativity extremely important need people social media supplement pharmacoepidemio question longheld beliefs propose new solutions innovative logic data many pharmacoepidemiologic studies use ideas hand especially pharmaceutical statistical methods assess data obtained studies follow industry areas employees need follow well ing marketing authorisation defined processes procedures maintain specific stand ards order guarantee safety quality pharma pharmaceutical laws regulations basic ceutical products principles help define processes procedures corsicos office miniature model treatment situation symbolises responsibility patient safety borne company dr christopher corsico among things responsible medicine safety boehringer ingelheim quality standards job develop applicable global stand course pharmacovigilance team responsible ards processes designed ensure compliance ensuring compliance standards regulations local laws regulations force worldwide countries boehringer ingelheim sells able define uniform global standards processes medications collect analyse information side effects medicines thus patients doctors ultimately rely ensure employees comply information printed medicines package leaflet crucial standards end ones bear responsibility ensuring patient safety protecting public health relates use employees regardless work medicines boehringer ingelheim responsible reporting potential side effects pharmacovigilance unit become aware record precisely side effects occurred extent events use variety methods ensure occurred circumstance employees aware reporting obligations including occurred course treatment collecting use online training modules addition carry data complex process differences checks regular intervals ensure employees people deal standards worldwide complying requirements moreover health authorities local countries also regularly examine drug safety colleagues pharmacovigilance comply system precisely compliance public health standards standards boehringer ingelheim means abiding rules ensuring wellbeing ever standards flexible enough allow individual patients taking medications countries meet specific local reporting requirements strictest pharmaceutical laws regulations detailed information pharmacoepidemiology available world come european union canada australia article professor sebastian schneeweiss pharmaco usa system designed comply standards epidemiologist harvard medical school boston annual report boehringer ingelheim independent dr michael siebler ingelheim germany age head company archive chance also enabled company move forward without strategy however little would come says head company archive cha nce st rat egy ridgefield usa dr rachel kroebarrett age director research global skill center new biological entities search therapeutic antibodies based clear strategy little left chance annual report boehringer ingelheim living contrasts independent albert boehringers attitude guides us day recognise opportunities utilise independent thinking turns chances success stories many strategic planners chance occurrences annoying journalist siebler charge historical archive yet frequently precisely chance occurrence makes boehringer ingelheim grndervilla founders resi many strategies possible first place dence companys head office site ingelheim presents entrance hall visitors leads discovery catapresan one entered creaking staircase woodpanelled conference room annals medicinal history october secretary head medicoscientific research put several history repeatedly influenced creative drops clonidine new active ingredient colds attitude chance discoveries head company boehringer ingelheims research department nose archive adds also applied master stroke young albert boehringer tartar factory nieder experiments kind quite common time ingelheim paying searched desperately new started breathing heavily also fell products wanted produce citric acid using fungi deep sleep extremely weak pulse low blood experiment failed since wooden casks using pressure slept hours research managers sterile bacteria entered leaving foulsmelling lactic acid boehringer ingelheim astonished experiments behind subsequently confirmed never previously observed animal experiments research scientists chance discourage boehringer however fired discovered extremely effective way lowering blood ambition instead obstinate downright stubborn pressure tablet form active ingredient later named relates siebler recognised opportunity made catapresan proved gift patients company use boehringer convinced tanneries food manufacturers pharmaceutical companies practical benefits strong demand catapresan patients lactic acid process created market new physicians well explains dr michael product boehringer ingelheim soon producing siebler excellent example chance influence industrial scale recognising chance offered oppor destiny company essentially archaeologist tunity turned right extremely lucrative blood pressure treatment catapresan proved gift patients company first patent granted baking powder original certificate archived founders villa first time company making real money com adrenaline substitute adrenaline considered ments siebler unstable difficult control austrians unable find buyer however farreaching consequences boehringer medical director boehringer ingelheim time ernst sufficient funds available begin production oppenheimer sensed development potential al kaloids also able take even better care social preparation despite becoming laughing stock wellbeing employees industry bought licences chance discovery lactic acid company would perhaps longer exist says siebler know least short time later turned sympatol far better anyone thought effect weaker boehringers way dealing unforeseen discovery natural adrenaline lasted longer oppenheimer presumably also influenced strategy offered product purely chance fact em ployees later generations researchers company bought however extremely farreaching de comments siebler unexpected reaction didnt necessa cision says siebler describing amazing story says rily regarded accident right lot corporate culture allowed colleague right place able recognise reward sympatol became one companys opportunity chance discovery try make something important products marked entry treatment addition however called day still cardiovascular diseases calls special degree scientific experience wellfounded knowledge intuition boehringer ingelheim work adrenaline deriva tives also represented start modern systematic drug one occasion substances search known highthroughput screening meanwhile discovered chance enabled boehringer ingelheim automated laboratory systems test tens thousands sub progress case sympatol small austrian stances every day socalled standardised target proteins company offered boehringer ingelheim licences produce entities attach effect appears annual report boehringer ingelheim living contrasts independent research new biological entities extremely targeted good strategy planning help identify opportunities focus increase probability success one variants known hit basis extremely rare says dr rachel kroebarrett speaking hits drug developers continue research experience american biochemist working attempt improve statistical chance discovering almost ten years pharmaceutical research boehringer thing new ingelheim usa since completing studies fascinated research biological substances even systematically controlled research kind proteins subsequently resulted becoming unexpected repeatedly happens example turns one first scientists perform research new biological antihiv medicine viramune also used entities nbes boehringer ingelheim small team protect children mothers aids infection set birth nintedanib active ingredient cancer also proves effective treatment idio contrast traditional medicines sympatol pathic pulmonary fibrosis ipf way new indications active molecule consists atoms sometimes show second third look reference case large molecules proteins scientists ask right questions explains siebler contain atoms nbes antibodies unfortunately downside research new biological entities swallowed tablet form since would digested become ineffective stomach injected search new small molecule entities traditional upside however development per pharmaceutical research painstaking process hits formed significantly targeted strategic fashion due nature nbes explains kroebarrett due changed scientific standards active ingredient nevirapine viramune alone longer recommended treatment option indication director biotherapeutics boehringer ingelheims try minimise reliance luck much possible highthroughput screening represented start modern systematic drug research global skill center nbes ridgefield connecticut todays competitive cost conscious world try heads team research scientists starts minimise reliance luck much possible says specific protein know causes damage disease kroebarrett path followed way target patient kroebarrett explains researchers protein finding specific optimised antibody clearly isolate protein administer laboratory animals defined biochemist colleagues meanwhile subsequently produce antibodies fight invader perfected entire sequence steps process even end whole range antibody variants says kroe researcher given sufficient freedom things differ barrett tested protein one ently try something new test tube way ensure innovations remain possible process similar highthroughput screening adds allowing unexpected happen also traditional medical research difference instead means scientists need prepared unexpected testing millions variants nbe researchers test ready seize scientific opportunities kroebarrett tens thousands know looking says even highly technologydriven structured much earlier stage adds kroebarrett best antibodies research department st century chance repeatedly selected members global skill helps team stay one step ahead researchers centre begin alter protein sequence antibody looking antibody combat rheumatoid arthritis way accepted human body chronic systemic inflammatory disorder primarily strategy team already contributed develop affects joints implementation screening strategy ment three antibodies cluding specific reversal agent al lowed identification antibody tests anticoagulant pradaxa submitted chance definitely played role help accelerate success regulatory approval usa europe good planning key annual report boehringer ingelheim group management report group management report information group companies report economic position report postbalance sheet date events report opportunities risks report expected developments annual report boehringer ingelheim group management report information group companies group management report information group companies groups business model boehringer ingelheim familyowned company boehringer ingelheim also one worlds leading founded based ingelheim germany providers veterinary medicines veterinary product company focussed research development highest net sales swine vaccine ingelvac production sale innovative pharmaceutical prod circoflex used porzine circovirus type ucts help improve health quality life bring major therapeutic advances another major growth driver boehringer ingelheim affiliated companies approximately employ field biopharmaceuticals segment deals ees group achieved net sales eur billion research development biosimilars con making one worlds top pharmaceutical companies boehringer ingelheims business activities cover prescription medicines consumer health care ani net sales business eur million mal health biopharmaceuticals industrial customers prescription medicines boehringer ingelheim 's major focus prescription medicines respiratory disease cardiovascular disease metabolic disease oncology diseases central nervous system immunology previous years consumer health care spiriva used treat chronic obstructive pulmonary disease copd biggest revenue contributor micardis well established years used treat animal health high blood pressure pradaxa used prevent stroke patients atrial fibrillation thrombo embolic disease also account large part com panys success trajenta upwards tra biopharmaceuticals jectory used treat type diabetes also driving growth boehringer ingelheim terms consumer health care mucosolvan industrial customers sales buscopan dulcolax pharmaton top selling products net sales region eur million research development rd building companys mission statement boehringer ingelheims primary aim develop innovative medi cines therapies diseases yet satisfactory treatment available aim times make major contribution areas need treatment high occupy leading position europe major indication areas asia order achieve goals strategically essential tech australia africa nologies continuously improved new technologi americas aaa cal approaches systematically examined boehringer ingelheim draws global network exper tise academic groups interaction public research institutions biotech companies addition expanding product portfolio partnership agreements systematic inlicensing technolo gies products example boehringer ingelheim tract manufacturing terms business field launched partnership curevac finan boehringer ingelheim one worlds leading con cial year order develop immunotherapy tract manufacturers biopharmaceuticals treatment lung cancer majority boehringer ingelheims net sales boehringer ingelheims successful research develop achieved regions america ment activities innovativeness basis europe however importance asia groups positive growth previous years inhouse australiaafrica aaa continuing increase research development also continue top net sales coming aaa region priority future example consistent three biggest markets usa japan germany implementation strategy technology centre accounted sales last year biberach inaugurated december future pilot facility manufacture innovative aim boehringer ingelheim drive develop substances required clinical trials invest ment existing product portfolio organic ments facility amounted around eur million growth progressing cooperation network external partners boehringer ingelheim oper financial year employed average ates major research development centres biberach people research development sites hanover ingelheim germany ridgefield total around eur billion invested st joseph usa vienna austria supported two research development new medicines corre smaller facilities kobe japan milan italy sponding groups net sales thus also level previous year forecasted annual report boehringer ingelheim group management report information group companies research development expenditure eur million net sales prescription medicines expenditure eur million prescription medicines net sales average number employees investments tangible assets without investments infrastructure eur million human pharmaceuticals phase iii clinical trial programm tovito key phase boehringer ingelheim carried research develop iii data reported trial program ment businesses prescription medicines results week vivacito study demonstrated consumer health care facilities usa germany significant improvement lung function hours austria italy japan last year many registrations tiotropium olodaterol respimat compared new products obtained submitted key focus monocomponents placebo data week research work following indica pivotal tonado studies showed tiotropium olo tion areas daterol respimat provided significant improvement lung function health related quality life respiratory diseases monocomponents cardiometabolic disorders cardiovascular metabolic disorders furthermore results anhelto studies oncology investigated striverdi olodaterol respimat diseases central nervous system combination spiriva tiotropium handi immunology haler copd also reported results showed compared monotherapies combining expenditure rd prescription medicines accounted striverdi respimat spiriva handihaler net sales generated business enabled patients breathe better cope easily daily life boehringer ingelheim long history treatment respiratory diseases leader field every second asthma patient still suffers symptoms years continued develop innovative despite current standard medication spiriva products provide significant medical benefit respimat offering first new class inhaled patients beside spiriva tiotropium prescribed asthma treatments decade new phase iii data maintenance therapy chronic obstructive p ulmonary reported comprehensive unitinaasthma disease copd worldwide company broad clinical trial programme designed evaluate efficacy respiratory portfolio market also research safety spiriva respimat patients asthma development study showed oncedaily tiotropium delivered via respimat inhaler effective well tolerated since many seriously ill patients copd therapies adult patients across asthma severities single substances lead sufficient improve ment lung function effectiveness safety addition results pivotal primotina tiotropium olodaterol respimat investigated asthma phase iii trials demonstrated spiriva respimat addon icslaba inhaled corticos stroke prevention atrial fibrillation af fda teroidlongacting betaagonists maintenance therapy conducted study pradaxa everyday clinical prac significantly improved asthma symptoms patients tice using data medicare patients data likely improve asthma control compared showed remarkably consistent results compared usual care alone results add existing evidence rely study findings established positive efficacy safety spiriva respimat patients riskbenefit profile pradaxa stroke prevention remained symptomatic despite treatment af additionally results two studies least icslaba everyday clinical practice data conducted walter reed national military medical center brigham first data phase iii cadentinaasthma womens hospital also consistent results week study japanese patients also reported rely showed spiriva respimat treatment improved lung function adult patients asthma part commitment improving patient care continue experience symptoms despite ics boehringer ingelheim extended revolution without laba therapy safety balanced clinical study programme recircuit compared placebo redual pci respect esus studies fur ther investigate dabigatran different indications idiopathic pulmonary fibrosis ipf rare severely reverse ad study investigates idarucizumab debilitating fatal lung disease first results specific reversal agent dabigatran clinical setting pivotal phase iii inpulsis trials presented patients taking pradaxa american thoracic society ats biggest respiratory congress usa inpulsis trials indication area metabolic disorders focus enrolled patients across countries evaluating research development drugs treatment effect oral nintedanib mg twice daily diabetes together alliance partner eli lilly annual rate decline forced vital capacity fvc company continue conduct studies patients ipf weeks pivotal data define efficacy safety profile oral antihyper inpulsis trials showed nintedanib slows glycemic agents empagliflozin jardiance linagliptin disease progression reducing decline lung trajenta jentadueto combination metformin function broad range ipf patient types results several phase iii clinical trials published significantly reduces risk adjudicated acute showing empagliflozin sodium glucose exacerbations cotransporter sglt inhibitor combination certain diabetes therapies including insulin reduced focus boehringer ingelheims research blood glucose body weight blood pressure compared activities field cardiovascular disorders glimepiride commonly used treatment improve pradaxa dabigatran etexilate approved blood sugar control empagliflozin led statistically us food drug administration fda euro significant reduction blood sugar weight loss pean medicines agency ema treatment pre two years improvements systolic blood pres vention recurrence deep vein thrombosis dvt sure glimepiride associated increase body pulmonary embolism pe new indication weight systolic blood pressure cardio treatment already approved countries world vascular outcomes trial empa reg outcome wide additional approvals expected empagliflozin first cardiovascular outcomes study sglt inhibitor read study data investigational empagliflozinlina gliptin combination annual report boehringer ingelheim group management report information group companies tablet first presented major congresses showed clinically indication area immunology promising interim important sustained reductions blood glucose clinical study results phase ii study included people type diabetes either previously patients moderate severe psoriasis p resented untreaded treated metformin phase phase american academy dermatology aad annual iii study data new insulin glargine product meeting primary endpoint analysis week part alliance eli lilly company showed high response rate boehringer ingelheims also publically disclosed first time il inhibitor code bi data showed similar safety efficacy profile currently safety issue bi nearly doubled per marketed insulin glargine centage patients achieving least almost clear skin pasi status compared active comparator indication area oncology boehringer ingelheim study biologic ustekinumab efficacious therapy successfully advanced research development approved indication approximately pipeline compounds marketed treatments patients reached least almost clear skin aim providing new treatment options may offer weeks two doses substance pasi clin patients added therapeutic value contribute quality ical score determine severity extent skin life improvements involvement psoriasis results still confirmed trial data including respective two independent phase iii trials luxlung phase iii results medical community aad consid luxlung showed patients whose tumours ered results exceptional common egfr mutation deletion exon del lived one year longer treated consumer health care boehringer ingelheim received firstline giotrif afatinib brand name gilotrif new marketing authorisations globally one usa compared standard chemotherapy overall mucoangin ambroxol sore throat spray survival secondary endpoint giotrifgilotrif company launch throughout europe first epidermal growth factor receptor mucoangin sore throat spray indicated pain relief egfr targeting agent demonstrate overall sur acute sore throat vival benefit compared chemotherapy firstline treatment nonsmall cell lung cancer nsclc patients animal health egfr mutations approved research development work field animal countries worldwide patients indication health boehringer ingelheim focuses innovative vac cines primarily protection livestock pets area central nervous systems cns diseases well pharmaceutical products different compounds potentially treat schizophrenia alzheimers disease clinical development facilities usa germany china mexico two indications clinical testing phase ii run japan denmark india netherlands focus ning deciphering brain circuitries cognition research new drugs development future underlying mechanism actions human brain therapeutic solutions since many vaccines based focus cns discovery research local pathogens pathogen variants imperative aim finally develop effective innovative treatments present key market regions local many socalled neuropsychiatric disorders cns research development production facilities boehringer ingelheim includes research activities fields psychiatry including treatmentresistant addition also saw around eur million depression invested expansion existing facilities well construction centre clinical research china products reliably high quality standards investments demonstrate companys commit internal group customers well external industrial ment intention sustainably strengthen posi clients tion animal health chemical pharmaceutical facilities animal health products boehringer ingelheim received covered area pharmaceutical chemical man product authorisations around world ufacturing pcm area interface december example eu commission issued development activities batch production division approval bovela innovative cattle vaccine responsible compliance high quality stand bovine viral diarrhoea bvd bovela first ards organising new product launches registered vaccine europe protect vari production innovative products entire life ants virus bvd bvd vaccine also cycle challenging terms tech first live virus disease also nology processes involved administered pregnant animals guidance third party management pm europe approval documents also submitted division network contract manufacturers focuses two improved vaccines porcine respiratory gmp compliant manufacture products reproductive syndrome prrs addition two salmo already advanced stage life cycle nella vaccines pigs enterisol received approval usa additional indication salmonella enterica june boehringer ingelheim announced thus expanding protection available us food drug administration fda withdrawn potentially zoonotic diseases warning letter following inspection production facilities ingelheim biopharmaceuticals warning letter issued boehringer ingelheim worked focus boehringer ingelheims research activities intensively measures optimise quality manage biopharmaceuticals lies primarily research ment systems compliance processes culminating development biosimilars finishing withdrawal warning letter continue phase study bi biosimilar avastin improve quality processes future order phase studies completed bi provide patients high quality products biosimilar rituxanmabthera patients rheumatoid arthritis bi biosimilar plans expand respimat production humira healthy volunteers first biosimilar facilities dortmund given goahead follow programmes progressed several regulatory ing investment eur million boehringer interactions phase iii studies start ingelheim increasing production capacity respimat soft inhaler million units per year production create around new jobs end human pharmaceuticals respimat soft inhaler propellantfree soft mist global production network consisted inhaler used standard application facilities countries production device future respiratory products locations group operates pharmaceutical facilities three chemical facilities four biopharmaceutical locations financial year boehringer ingelheim one medical technology facility many years chemicals inc production facility virginia usa experience production facilities enable us produce closed company previously produced pharma annual report boehringer ingelheim group management report information group companies ceutical substances group thirdparty construction laboratory complex pro businesses followed smooth transition duction biopharmaceutical clinical trial supplies products internal external suppliers successfully completed facility gone operation addition sale assets held bedford laboratories ben venue facility hikma pharmaceuticals plc safety environmental protection successfully completed second half year protection employees facilities bedford laboratories business unit responsible environment well sustainable use natural generic injectables owned ben venue inc usa resources promotion environmental awareness primarily worked acute care clinics purchasing major components companys mission statement groups cancer treatment centres prime importance boehringer ingelheim social environmental responsibility anchored animal health corporate philosophy many years company animal health boehringer ingelheim predominantly strives maintain natural resources advocates environ active north central america well europe mental awareness inside outside company production network consisting four facilities observing social ecological concerns way vaccine production network contract manufac ensure enjoy sustainable financial success turers pharmaceutical products construction new chinese facility taizhou continued apace groupwide company developed binding stand location asia soon joining pro ards terms environmental protection health duction network major component animal safety work internal guidelines reflect respec health growth strategy facility focus man tive countryspecific legal requirements significantly ufacture vaccines porcine avian diseases exceed many cases chinese market within boehringer ingelheim infrastructure safety biopharmaceuticals environment engineering isee division responsible biopharmaceutical activities boehringer ingelheim introducing reviewing internal environmental germany biberach austria vienna usa fremont occupational safety guidelines compliance china shanghai comprise manufacture standards status environmental employee ownbrand marketable products actilyse metalyse protection examined regular audits order con imukin beromun development biosimilars tinuously identify potential areas improvement well contract manufacturing thirdparty cus tomers company covers entire biopharmaceutical one example continuous improvements environ value chain genetic development cell mental protection analysis decontamination manufacturing filling finished soil around ingelheim facility project pharmaceutical product product launch initiated extensive undertaking contin supplying global market comparison previ ued order ensure relevant environmental ous year saw overall increase capacity utilisa protection result technical progress issues tion production facilities analysed precisely today experts fields geochemistry environmental toxicology also pushed ahead establishing new engineering consulted advice implementing facility shanghai various biopharmaceutical devel measures opment services chinese international customers order make contribution towards reducing global ideally equipped deal challenges ahead co emissions set ambitious goal part comprehensive training system place reducing co emissions com great importance acquisition technical pared values aim putting skills also development social expertise focus potential energy savings reductions emis sions promoting exchange expertise addition competitive salaries boehringer ingelheim companys facilities coordinating projects offers benefits employees include international level range company pension plans flexible homebased work options countless healthrelated benefits health safety employees top priority talent management approach major element boehringer ingelheim reflected high global corporate strategy helps maintain employabil safety standards guidelines well imple ity staff promote wide range opportunities mentation safety culture groupwide bi safe innovation work enable employees nurture initiative launched aims talents develop individuals reduce number workplace accidents since rolled almost international facilities vocational training always major importance order achieve related target accident frequency boehringer ingelheim offering young people career rate afr accidents per million hours worked opportunities face social responsibilities focus global measures human behaviour time also enables us secure talented part initiative members senior management wellqualified workforce young professionals entire workforce play key role proactively taking backdrop demographic change every year boehringer responsibility safety safety ingelheim takes around apprentices german colleagues afr saw facilities different scientific technical com improvement prior year mercial vocations employee reporting one company 's aims strengthen appeal people employed worldwide boehringer ingelheim top employer current group comparison previous year corre future employees focus recruiting sponds increase regional point specialists management staff fields produc view number staff america reduced tion quality part boehringer ingelheim number employees europe aaa region careers website social media presence increased restructured major digital communication channels average number employees region boehringer ingelheim recipient various awards americas including award association employed europe academics executives chemical industry asiaaustraliaafrica aaa award proof pioneering approach longterm strategy boehringer ingelheims human resources hr work addition company awarded major success factor positive growth boehringer careerenhancing fair trainee programme seal ingelheim innovative dedicated reliable staff discover trainee programme accordingly particularly committed actively developing supporting employees ensure annual report boehringer ingelheim group management report information group companies report economic position boehringer ingelheim also received employer sector project facilities specific period time year award china january germany successful implementation eir programme march received top marks auditors part mmh initiative rewarded international independent top employers institute highprofile hr excellence award management major hr categories primary benefits second development category ary benefits corporate culture seal proof great appeal development opportunities integrating variety experiences cultural back company employees potential grounds personalities boehringer ingelheim creates recruits openness different approaches opinions living motto value innovation create corporate citizenship working environment open diversity differ taking social responsibility seriously major part ences one fundamental pillars cor boehringer ingelheim corporate culture wide porate culture example company first range projects live social responsibility germany develop action plan order towards patients employees families well implement goals united nations disability people need countries regions com rights convention workplace boehringer ingelheim pany business companys activities also received government recognition work focus protecting maintaining environment commendation german federal ministry boehringer ingelheim received responsible care labour social affairs award german chemical industry association commitment responsible attitude boehringer ingelheim showed commitment last year mission million getting major part commitment social responsibility heart stroke awarenessraising initiative also initiat making health mmh initiative partner ing various projects educational events initiative ship boehringer ingelheim global non launched boehringer ingelheim governmental organisation ashoka existed promotes projects raise awareness atrial fibrillation past four years aim partnership inte associated risk stroke well improving grate health major factor peoples lives around public perception independent organisations world including within families social around world involved initiative environment identifying supporting promising awarenessraising events carried cities ideas lead improved health order achieve part initiative supported german making health currently promotes cardiac society selected social entrepreneurs around world attempting come effective solutions boehringer ingelheim continued actively support healthcare sector research science culture many years longterm partnerships academic institutions serve social commitment within company also encour line groups systematic focus research devel aged boehringer ingelheim boehringer opment since example boehringer ingelheim ingelheim employees countries com invested eur research projects investi mitted mmh initiative one major pillars gating infections porcine circovirus type pcv executive residence eir staff development pro associated diseases addition supporting gramme programme gives young managers oppor sponsoring scientific activities scientists also awarded tunity support social entrepreneurs healthcare annual boehringer ingelheim fens research award group management report information group companies report economic position neuroscience heinrichwielandprize view assumed little boehringer ingelheim foundation research bio change terms restrained economic growth logically active substances systems germany growth predicted primarily result increased consumer confidence supported positive situation labour market increasing report realterm salaries economic p osition average rate inflation prices germany decreased compared previous macroeconomic environment year measured consumer price index pri financial year global economy grew mary reason decrease prices food thus exceeding level previous year stuffs energy rate inflation whole still slightly lower expected partly due eurozone thus also lower pre ongoing economic problems within eurozone vious year addition rate economic growth emerging developing countries continued slow addition euro major currencies result countryspecific factors ongoing crisis boehringer ingelheim group us dollar usd eastern europe emerging economies showed japanese yen jpy relation us dollar significantly sharper decline expected main euro experienced ongoing decrease value fluctuating driver global growth strong domestic demand usdeur may usdeur brought upswing usa uk december last financial year exchange rate improvements japanese economy largely euro japanese yen fluctuated triggered monetary fiscal policy jpyeur october jpyeur december reaching lowest point october yen signifi global economy expected grow cantly depreciated value euro towards slightly higher rate case three end year effects particular play role restrained growth looks set continue eurozone expect growth around past financial year slight increase addition assumed global pharmaceuticals market also improved perfor chinas growth continue slow increase mance compared previous year trend gdp around negatively impacting emerg driven increasing demand innovative drugs ing economies contrast usa uk otc medicines well pharmaceuticals emerg forecasted experience growth rates ing economies china brazil russia india respectively making growth drivers showed growth rates far average among advanced economies lead established industrialised countries market slight increase global growth depressed health policy measures price regula tion well increased cost pressure health economic performance germany increased systems patented pharmaceuticals particular experi past year starting positive first enced radical changes market environment quarter german economy slowed year growth rates established regions lower progressed major drivers positive developments average labour market one hand dampened weak economic growth within eurozone annual report boehringer ingelheim group management report report economic position course business recorded drop sales revenue longterm sustainably successful business develop eur million around groups turnover ment basis independence group achieved region combined stable results solid financing net sales region currency focus boehringer ingelheims strategy pre eur million change adjusted vious years based approach principles americas year review europe asiaaustraliaafrica boehringer ingelheim year revealed aaa challenges terms decreasing net sales also year took major steps towards securing future total decreases sales recorded resulted challenges warning letter fda difficult market environment particularly us legal dispute regarding pradaxa sale usa brought ongoing price reductions major assets us subsidiary ben venue laborato result high cost pressure health care system ries inc successfully managed concluded pushed ahead renewal product portfo addition various measures costsaving initiatives lio successful launch promising product inno created important basis positive developments vations including oncology drug giotrif years come gilotrif launches along wellstocked product pipeline research development ena boehringer ingelheim generated net sales eur ble boehringer ingelheim resume growth course million financial year fell short future previous years level eur million corresponding decrease case develop boehringer ingelheim achieved operating result ments foreign exchange markets associ eur million corresponding return sales ated exchange rate effects negative impact adjusted increase comparison previous effects net sales declined meant year line predictions negative effects previous years forecast stable sales increased costs associated warning achieved letter fda restructuring costs us legal dispute regarding pradaxa offset positive effects americas region group achieved net sales costsaving measures increased efficiency eur million represents decrease well proceeds sale major assets compared previous year around us subsidiary ben venue laboratories inc total sales americas region biggest sales market boehringer ingelheim eurodollar key figures eur million change exchange rate negative impact earnings net sales situation adjusted currency effects decrease operating income sales amounted asiaaustraliaafrica return net sales aaa region continues grow significance group net sales eur million results operations adjusted currency effects boehringer boehringer ingelheims business activities divided ingelheim showed growth prescription medicines consumer health care animal region past financial year company made health biopharmaceuticals industrial customers around global sales europe region also regard regional distribution sales net sales businesses currency eur million change adjusted none three regions registered growth pre prescription medicines scription medicines americas share consumer health care far largest market region boehringer animal health ingelheim generated net sales eur million biopharmaceuticals corresponds change compared industrial customers previous year currencyadjusted sales per sales formance important market us prescription medicines greatest impact performance americas sales around overall sales prescription medicines eur million decreased pri main pillar boehringer ingelheims business activ marily result health care reforms along ities sales amounted eur million unfavourable exchange rate movements equivalent change currency net sales region adjusted compared previous year decrease eur million change sales largely due increased pressure research americas driven pharmaceutical companies result health europe care reforms usa asiaaustraliaafrica aaa case previous years spiriva treat ment copd biggest revenue contributor secondbiggest market europe accounted accounting sales eur million report sales eur million decrease sales ing period however level compared thereby amounted recorded previous year eur million currencyadjusted sales germany france significant decrease sales spiriva big spain particular lower previous year gest sales market usa result price pressure aaa region achieved net sales eur million second biggest revenue contributor boehringer equivalent total sales prescription ingelheim anticoagulant pradaxa recorded sales medicines region showed slight decrease com eur million corresponds previous pared last year currencyadjusted years level primarily due currencyrelated decline sales japan boehringer ingelheim generated micardis drug used treat high blood pressure net sales eur million corresponds achieved sales eur million last change compared previous year year expected decline resulted loss ex clusivity additional markets consumer health care market environment seasonal fluctuations net sales eur million change difficult business eastern europe sales con spiriva sumer health care business pradaxa currencyadjusted compared previous year micardis business boehringer ingelheim generated sales combivent amounting eur million annual report boehringer ingelheim group management report report economic position biggest revenue contributors consumer sales products livestock accounted largest health care segment buscopan dulcolax share eur million corresponding mucosolvan pharmaton products generated entire animal health segment previous sales significantly eur million year biggest revenue contributor swine vac case previous year buscopan cine ingelvac circoflex accounting eur million strongest performer eur million growing sales pet segment generated eur million dulcolax also showed positive development corresponds share sales increasing eur million con trast experiencing significant boost net sales eur million change mucosolvan registered decrease year ingelvac circoflex achieving net sales eur million metacam ingelvac prrs duramune net sales eur million change buscopan dulcolax growth animal health segment sig mucosolvan nificant americas region overall biggest sales pharmaton market boehringer ingelheim grew currencyadjusted eur million us market considering region whole europe generated particular net sales increased eur million highest net sales eur million corresponds share global net sales consumer health increase currencyadjusted care business however european business experienced aaa region also achieved positive growth compared decrease sales currencyadjusted previous year registering sales eur million boehringer ingelheims significant market germany china achieved impressive growth net also showed dip sales sales eur million aaa region ended financial year net europe region boehringer ingelheim sales amounting eur million increase reported slight growth financial year compared previous year currency currencyadjusted net sales germany adjusted region therefore accounted remained stable level previous year uk boehringer ingelheims consumer health care business enjoyed significant growth americas region third largest sales market biopharmaceuticals consumer health care business ended financial year biopharmaceuticals business consists contract slight decline sales currency manufacturing biosimilars sales biop adjusted compared previous year achieving harmaceuticals amounted eur million total net sales eur million decrease sales represented growth compared previous mainly largest market us year currencyadjusted animal health industrial customers sales sales products animal health segment increased industrial customer business consists third eur million corresponding party businesses field pharmaceutical chem increase previous year currencyadjusted ical production contract manufacturing business pharma chemicals net sales eur million financial year net income boehringer achieved corresponding decrease revenue ingelheim group totalled eur million currencyadjusted compared thus lower previous years level eur mil prev ious year lion presentation expenditure income financial position operating expenses boehringer ingelheim decreased boehringer ingelheim financial management strategy eur million financial year repre focuses securing liquidity minimising limiting senting change compared previous financial economic risks optimising cost year material costs exceeded last years value capital suitable capital structure financial coming eur million eur million activities therefore geared towards supporting result declining sales material costs business strategy level previous year represented share total sales personnel costs amounted international company exchange rate volatility eur million slightly higher significant impact boehringer ingelheims financial eur million corresponding personnel performance importance us business cost ratio associated supply relationships mean perfor mance us dollar constitutes greatest single risk depreciation accounting recorded decrease result international focus business eur million operating expenses declined activities foreign exchange risk calculated within compared previous year coming framework groupwide financial reporting eur million among things cost block hedged using derivative financial instruments nature includes commission licence payments scope measures set group dependent sales result costsaving effi guidelines regularly discussed approved ciency measures operating result forecast relevant committee standardised process slightly higher eur million eur million investments highly significant boehringer ingelheim strategic point view order secure long reporting period financial result amounted term success development group ongoing eur million eur million compared investments create basis profitable growth previous year largely attributable strategic development businesses interest effects within pension commitments total eur million invested tangible tax expenses amounted eur million past intangible assets year review financial year must noted regard provisions german commercial law shareholders order meet consistent positive demand personal taxes arising group business activities may respimat soft mist inhaler facilitate upcoming recognised tax expenses instead taxes launches spiriva respimat spiolto company presented part withdrawals group equity taking moved ahead expansion production capacity extraordinary effect account actual tax ratio dortmund ingelheim sites markedly higher figure shown profit investments amounting eur million respimat loss statement soft mist inhaler manufactured boehringer ingelheim microparts gmbh dortmund filled annual report boehringer ingelheim group management report report economic position report postbalance sheet date events report opportunites risks relevant active substances pharmaceu funds including securities within current assets stood tical production facility ingelheim sale worldwide eur million eur million addition eur million invested new office building ingelheim underlines strategic role due aforementioned changes group equity significance location group major amounted eur million addition equity growth market china boehringer ingelheim invested pension provisions longterm liabilities also avail eur million expansion able group long term total three manufacturing facilities chemical research items amounted eur million represent development laboratory shanghai research devel ing share total assets consequently opment fields human animal medicines longterm disposable capital covers intangible also remain top priority boehringer ingelheim tangible assets inventories trade accounts receivable future result additional investments made research development facilities germany provisions around higher last austria usa year eur million liabilities reduced eur million past financial year primarily cash flow stood eur million con result decreased bank liabilities due repayment stitutes decrease compared bank loans result higher provisions period compared previous year cash flow operating activities balance sheet respective balance sheet ratios increased eur million eur million round positive picture already shown finan previous years meant investments could cial position results operations combined financed entirely funds generated c ompany evaluation net assets financial position results total eur million invested tangible operations shows boehringer ingelheim assets eur million intangible assets terms soundly financed profitable company cash flow financing activities recorded flow funds amounting eur million result report postbalance repayments loans overall changes cash flow led increase liquid funds eur million sheet date events eur million net assets since end financial year financial year boehringer ingelheims total become aware events material signifi assets amounted eur million increase cance group companies could lead eur million compared previous reappraisal net assets financial position results year tangible intangible assets totalled eur mil operations lion fully covered consolidated equity end year financial assets totalled eur million eur million higher previous year inventories showed increase eur million trade accounts receivable rose eur million eur million liquid group management report report economic position report postbalance sheet date events report opportunites risks report opportunites individual risks risks important risks boehringer ingelheim exposed broken following specific categories financial risks legal risks production envi opportunity risk management ronmental risks personnel risks sectorspecific risks aim risk management system implemented boehringer ingelheim identify businessspecific risks risks identified concrete particular risks jeopardise continued appear controllable means specific manage existence company early possible assess ment procedures term abstract used case reduce reasonable level means risks completely controlled even suitable measures means targeted management procedures regardless probability occurrence assessing risks context holistic risk management also endeavour take account financial risks resulting opportunities opportunity management relevant financial risks broken based strategies objectives company follows currency risks credit countryspecific risks individual businesses operating business units well management financial investment risks integral part groupwide planning manage ment systems responsible businesses currency risks functions bear direct responsibility early sys global orientation business activities results tematic identification analysis use opportunities currency risks due exchange rate volatility particularly boehringer ingelheim researchdriven inno regard us dollar japanese yen group vative company current research development monitors quantifies risks regular intervals activities naturally considered relevant opportunity making predictable future business means detailed description projects illustrated relevant hedging strategies appropriate financial research development chapter instruments forward exchange contracts resultant risks subsequently designated con persons responsible businesses functions crete therefore controllable included process calculating assessing risks groupwide risk information system credit countryspecific risks ensures identified risks analysed assessed boehringer ingelheim exposed various credit carefully following appropriate classification countryspecific risks result international busi various categories adequate countermeasures initi ness activities portfolio trade accounts ated implementation consistently monitored receivable trade accounts payable identi fied extraordinary risks group beyond year review internal auditing performed tar usual level sector applies possible default geted routine audits well extraordinary audits around risks receivables largely hedged world addition adherence legal requirements economic political risks continue carefully internal group guidelines main focal points track credit countryspecific risks position functionality systems effectiveness internal respond negative changes timely manner controls prevention loss assets effi risks therefore regarded concrete ciency structures processes corresponding adjust ments optimisations initiated necessary annual report boehringer ingelheim group management report report opportunites risks report expected developments management financial investment risks us detect threats early stage commencing group pursues defensive investment strategy appropriate countermeasures defend legal position management financial assets reflected using legal means available us risks orientation portfolio focused european regarded concrete economic monetary union emu government bonds top credit ratings shortterm investments production environmental risks selected banks results concrete risk although us food drug administration fda withdrew warning letter issued legal risks following inspection ingelheim manufacturing business activities group exposed legal facility risk remained high significance risks distinction made regulatory liability group classified abstract quality manage patent protection risks ment systems compliance process optimised close cooperation fda order ensure com regulatory risks pliance current good manufacturing practices boehringer ingelheim exposed risks arising legal cgmp future disputes proceedings well official investiga tions legal administrative decisions ongoing order guarantee supply products future proceedings predicted regard market implemented measures guarantee resultant risks abstract reliable highquality supplies internal exter nal customers addition supplier management liability risks procurement side also involves building internal marketing sale pharmaceuticals exposed standby capacities result see risk concrete potential product liability risk boehringer ingelheim currently product liability insurance companys risks areas infrastructure safety environment risk profile absolutely guarantee however engineering isee proactively minimised insurance coverage maintained reason ensuring global adherence high safety standards able cost acceptable conditions sufficient appropriate emergency plans drawn protect boehringer ingelheim claim loss possible incidents kind practised sub potential claims losses jected comprehensive quality testing regular inter vals result measures risks classed furthermore product liability claims could tie sub concrete stantial financial resources management capacity detrimental companys image event personnel risks market considers product unsafe ineffec boehringer ingelheim like companies exposed tive result unexpected side effects regard demographic change resultant risk affec risk abstract ted lack appropriately qualified personnel risk substantial impact companys patent protection risks business activities potential risk therefore protection innovations trademark brand included longterm planning process many patent rights particular importance boehringer years acquired strategic significance result ingelheim research company commercial pro boehringer ingelheim counters risk means tective rights increasingly target attacks comprehensive personnel concept regardless breaches taken necessary precautions allow ethnic background gender religion offer com group management report report opportunites risks report expected developments pany employees development opportunities based pharmaceutical industry continue require sig vocational skills social expertise personal aptitudes nificant attention boehringer ingelheim willingness take responsibility accordance view competitiveness measures taken reduce needs company view countermeasures costs enhance efficiency successfully described risk regarded concrete launched thus creating solid basis future sectorspecific risks continue renew product portfolio boehringer ingelheim exposed business risks specific financial year company already set pharmaceutical industry risks current course back entry thera materialised past financial year changes us peutic area oncology following approval giotrif healthcare system increasing significance expansion activities field result impact boehringer ingelheim diabetes empagliflozin respiratory disease continue classed abstract olodaterol path continues follow approvals obtained us european addition loss exclusivity products estab authorities ofev treatment lung lished market risks associated devel disease ipf pradaxa therapy deep vein throm opment registration new products risks bosis pulmonary embolism striverdi respimat increasingly include changing restrictive requirements copd jardiance diabetes addition relating pricing reimbursement many sales second cancer drug vargatef also received eu approval markets frequently prices pharmaceutical prod thanks growth new products expected ucts subject state monitoring regula decrease net sales resulting loss exclusivity tion also price pressure cheaper generic drugs rights medicines provide offset caused state reimbursement systems boehringer leading moderate growth medium term ingelheim therefore keeping close eye various changes sales markets already started besides jardiance developed positively respond current developments costsaving product trajenta linagliptin used efficiencyimproving measures initiated treatment type diabetes well growth potential marketed part alliance overall statement risk situation boehringer ingelheim eli lilly company current perspective aware risks longterm collaboration joint development alone conjunction risks could lead marketing diabetes active ingredients con impairment companys assets financial position tinued also comprises active ingredients earnings could jeopardise continued existence ready market next years boehringer ingelheim light many changes health system significant growth impetus phar report expected maceutical industry coming year furthermore developments result changing conditions boehringer ingelheims major markets upheavals expected despite difficult market conditions expecting overall past financial year intense challenging increase sales compared previous year one boehringer ingelheim increasingly difficult currencyneutral basis following two years market environment posed major challenges entire annual report boehringer ingelheim group management report report expected developments declining sales due new product approvals sustainable organic growth therefore still takes prece listed dence shortterm profit targets confident achieve ambitious targets thanks great rd costs remained high keeping innovative strength based comprehensive portfolio strategy drive growth promote new products prospective products global presence future primarily products rd facili support highly qualified motivated employees ties invest area care close investiga continue stand vision value tion therapeutic benefit associated prospects innovation research develop innovative products success portfolio prospective products offer high medical benefits bring promising study outcomes along newly approved market aim endeavours make new drugs products significant sales potential justifies high available enable doctors treat patients level investment rd plan invest effectively currently possible research development new pharmaceutical products similar level year review addition patent expiry attacks patents major challenges facing researchdriven pharmaceuti cal industry increasing amount investment rd well bigger hurdles increased costs asso ciated product approvals context increasing cost pressure healthcare system singled particular reason fewer fewer companies prepared invest large amounts proper development new medicines legislative intervention pricing prescription medicines negative impact various markets increasing cost pressure pricing difficulties already influenced result financial year result boehringer ingelheim started react changes pharmaceutical market last year launched journey costsaving initiative point programme lower cost base order create potential investments secure companys longterm success company continue work journey initiative coming year result initial outlays necessary order implement measures effectively expecting operating result level last year familyowned company long history boehringer ingelheims primary aim maintain firms independence competitiveness longterm consolidated financial statements consolidated financial statements overview major consolidated companies consolidated balance sheet consolidated profit loss statement cash flow statement statement changes group equity notes consolidated financial statements auditors report annual report boehringer ingelheim overview major consolidated companies overview major consolidated companies c h boehringer sohn ag co kg boehringer ingelheim boehringer ingelheim boehringer ingelheim gmbh europe gmbh international gmbh germany p r austria p r austria r boehringer ingelheim boehringer ingelheim rcv forschungsinstitut fr molekulare pharma gmbh co kg gmbh co kg vienna pathologie gesellschaft mbh ingelheim vienna boehringer ingelheim boehringer ingelheim pharma gesmbh vienna vetmedica gmbh ingelheim belgium boehringer ingelheim microparts gmbh dortmund czech republic scs boehringer ingelheim comm v brussels boehringer ingelheim boehringer ingelheim sro biopharmaceuticals gmbh prague ingelheim china p boehringer ingelheim veterinary finland boehringer ingelheim research center gmbh co kg international trading shanghai hannover boehringer ingelheim co ltd shanghai finland ky espoo philippines norway boehringer ingelheim boehringer ingelheim phil inc manila norway ks asker poland boehringer ingelheim spzoo warsaw distribution p production r research development sole personally liable managing shareholder boehringer ag c h boehringer sohn grundstcksverwaltung gmbh co kg boehringer ingelheim auslandsbeteiligungs gmbh argentina r france p netherlands p taiwan boehringer ingelheim sa boehringer ingelheim boehringer ingelheim bv alkmaar boehringer ingelheim buenos aires france sas paris taiwan ltd taipeh boehringer ingelheim animal health operations bv alkmaar australia greece p thailand boehringer ingelheim pty ltd boehringer ingelheim ellas ae new zealand boehringer ingelheim north ryde athens thai ltd bangkok boehringer ingelheim nz ltd auckland brazil p india turkey boehringer ingelheim brasil boehringer ingelheim portugal boehringer ingelheim ilac quimica e farmaceutica ltda india private ltd mumbai ticaret istanbul paulo boehringer ingelheim lda lisbon solana agro pecuaria ltda unilfarma lda lisbon indonesia p united kingdom arapongas pt boehringer ingelheim boehringer ingelheim ltd singapore indonesia jakarta bracknell canada boehringer ingelheim boehringer ingelheim singapore pte ltd singapore ireland usa p r canada ltd burlington boehringer ingelheim boehringer ingelheim corp south africa ireland limited dublin ridgefield connecticut chile boehringer ingelheim pty ltd boehringer ingelheim boehringer ingelheim ltda randburg pharmaceuticals inc italy p r santiago de chile ingelheim pharmaceuticals pty ridgefield connecticut boehringer ingelheim ltd randburg boehringer ingelheim italia spa reggello usa corporation china p bidachem spa ridgefield connecticut south korea boehringer ingelheim shanghai fornovo giovanni roxane laboratories inc pharmaceuticals co ltd shanghai boehringer ingelheim korea ltd columbus ohio boehringer ingelheim china japan p r seoul boehringer ingelheim investment co ltd shanghai vetmedica inc boehringer ingelheim vetmedica nippon boehringer ingelheim spain p st joseph missouri china investment co ltd shanghai co ltd tokyo boehringer ingelheim boehringer ingelheim animal health ssp co ltd tokyo boehringer ingelheim roxane inc columbus ohio espaa sa barcelona operations china co ltd taizhou boehringer ingelheim boehringer ingelheim vetmedica japan co ltd boehringer ingelheim sa barcelona fremont inc columbia p tokyo europharma sa barcelona fremont california boehringer ingelheim boehringer ingelheim sa seiyaku co ltd yamagata laboratorios fher sa barcelona bogot venezuela boehringer ingelheim japan inc tokyo sweden boehringer ingelheim ca caracas denmark p boehringer ingelheim ab stockholm boehringer ingelheim mexico p r danmark copenhagen boehringer ingelheim switzerland promeco sa de cv boehringer ingelheim ecuador mexico city schweiz gmbh basel boehringer ingelheim vetmedica boehringer ingelheim del ecuador pharmaton sa lugano sa de cv guadalajara cia ltda quito annual report boehringer ingelheim consolidated financial statements consolidated balance sheet consolidated profit loss statement c h boehringer sohn ag co kg ingelheim consolidated balance sheet assets millions eur notes intangible assets tangible assets financial assets fixed assets inventories accounts receivable assets securities cash cash equivalents current assets deferred charges prepaid expenses deferred taxes total assets liabilities equity millions eur notes shareholders capital group reserves balance sheet currency conversion difference net income equity minority interests group equity negative difference acquisition companies provisions accounts payable liabilities deferred charges deferred taxes total liabilities equity explanation see relevant section notes consolidated financial statements consolidated financial statements consolidated balance sheet consolidated profit loss statement c h boehringer sohn ag co kg ingelheim consolidated profit loss statement millions eur notes net sales changes inventories internal work performed capitalised operating income total revenues material costs personnel costs amortisation intangible depreciation tangible assets operating expenses operating income financial income holding income income taxes taxes income taxes thirdparty share net income explanation see relevant section notes consolidated financial statements due legal requirements disclosure shareholders personal taxes arising consolidated business activities tax expenses allowed taxes shown withdrawals accrued group capital items consolidated profit loss statement show value due rounding millions eur disclosed annual report boehringer ingelheim consolidated financial statements cash flow statement statement changes group equity c h boehringer sohn ag co kg ingelheim cash flow statement millions eur income taxes including thirdparty share writedownswriteups fixed assets change provisions pensions cash flow change provisions noncash income expenses gain loss disposals fixed assets change inventories change accounts receivable assets related investing financing activities change trade accounts payable liabilities related investing financing activities cash flow operating activities investments intangible assets investments property plant equipment investments noncurrent financial assets proceeds disposals intangible assets proceeds disposals tangible assets proceeds disposals noncurrent financial assets cash receipts disposal subsidiaries cash flow investing activities cash receipts fromcash payment owners minority shareholders cash proceeds borrowingsrepayments loans cash flow financing activities change liquid funds cash relevant transactions changes liquid funds due exchange rate movements changes group structure financial funds financial funds excl fixedasset securities liquid funds securities within fixed current assets source funds use funds consolidated financial statements cash flow statement statement changes group equity c h boehringer sohn ag co kg ingelheim statement changes group equity sharehol accrued thereof cur minority thereof cur millions eur ders capital group capital rency effects equity interests rency effects group equity balance withdrawals net income changes balance contributions withdrawals net income changes balance shareholders capital consists equity c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg capital consists limited partners capital contribution shareholders personal taxes arising consolidated business activities shown withdrawals accrued group capital items statement changes equity show value due rounding millions eur disclosed annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements c h boehringer sohn ag co kg ingelheim notes consolidated financial statements general principles general principles consolidated financial statements boehringer ingelheim financial year prepared accordance section german commercial code hgb line legal requirements prepare consolidated financial statements group management report section et seq hgb accordance section hgb consolidated financial statements consist consolidated balance sheet consolidated profit loss statement notes consolidated financial statements cash flow statement statement changes group equity consolidated financial statements prepared euro accordance section conjunc tion section hgb improve clarity consolidated financial statements individual items consolidated balance sheet consolidated profit loss statement combined items presented explained separately notes additional disclosures required individual items also found notes information consolidated companies parent company boehringer ingelheim group c h boehringer sohn ag co kg ingelheim boehringer ag ingelheim sole personally liable managing shareholder company besides c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg whose general partner controlled c h boehringer sohn ag co kg boehringer ingelheim group consists total affiliated companies germany abroad addition c h boehringer sohn ag co kg c h boehringer sohn grundstcksverwaltung gmbh co kg companies c h boehringer sohn ag co kg directly indirectly holds majority voting rights included consolidated financial statements full consoli dation rules accordance section hgb companies included consolidation reporting year individually collectively insignificant terms net assets financial position results operations group total amount sales equity net income companies included consolidation account less aggregated group financial statements totals companies also classified associates accordance section hgb due lack significance ongoing restrictions disposal two companies account articles association consolidated accordance section hgb total number affiliated companies increased four compared previous year one company sold four companies founded one former related company considered affiliated company following subsidiaries exempted reporting disclosure obligations section hgb boehringer ingelheim gmbh ingelheim boehringer ingelheim europe gmbh ingelheim boehringer ingelheim vetmedica gmbh ingelheim boehringer ingelheim secura versicherungsvermittlungs gmbh ingelheim boehringer ingelheim grundstcksgesellschaft mbh ingelheim boehringer ingelheim finanzierungs gmbh ingelheim boehringer ingelheim rd beteiligungs gmbh ingelheim boehringer ingelheim venture fund gmbh ingelheim following subsidiary companies exempt duty prepare disclose annual financial state ments management reports accordance section b hgb c h boehringer sohn ag co kg ingelheim c h boehringer sohn grundstcksverwaltung gmbh co kg ingelheim boehringer ingelheim pharma gmbh co kg ingelheim c h boehringer selbstmedikation kg ingelheim boehringer ingelheim veterinary research center gmbh co kg hanover consolidation methods inventories fixed assets receivables liabilities income expense items transactions companies included consolidation eliminated part debt consolidation procedures accord ance section hgb procedures eliminate intercompany profits accordance section hgb income expenses consolidation procedures accordance section hgb revaluation method applied including subsidiary companies consolidation first time accordance section hgb companies consolidated first time date company became subsidiary carrying amount shares held parent company offset corresponding equity subsidiary equity carried amount fair value assets liabilities prepaid expenses deferred income special reserves included consolidated financial statements time con solidation remaining balance offsetting capitalised goodwill annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements currency translation assets liabilities resulting foreign currency transactions translated using middle spot exchange rate balance sheet date realisation principle section conjunction section hgb historical cost convention section conjunction section hgb applied items remaining term one year consolidated financial statements financial statements foreign subsidiaries domiciled state outside eurozone denominated foreign currency converted euro accordance section hgb using modified closing rate method using modified closing date rate method asset liability items annual financial statements prepared foreign currency translated euros using average spot exchange rate closing date exception equity translated using historical rate items included profit loss statement translated euros using average rate resulting translation difference generally reported within consolidated equity reserves difference equity currency translation annual financial statements countries hyper inflation parts difference recognized profit loss statement improve true fair view consolidated finan cial statements important currencies group developed follows reporting year basis eur yearend rate average annual rate us dollar japanese yen pound sterling canadian dollar accounting policies fixed assets acquired intangible assets tangible assets carried cost less scheduled straightline amortisation depreciation determined consideration technical economic circumstances based following useful lives intangible assets years buildings years technical equipment machinery years equipment operating office equipment years straightline depreciation amortisation used consolidated financial statements addi tional writedowns recorded reflect impairments value assets considered permanently impaired production costs include materials labourmanufacturing costs appropriate portion materials labour overheads depreciation fixed assets extent caused production capitalised intangible assets finite useful lives goodwill firsttime consolidation shares usually amortised period five years useful life ten years applied goodwill boehringer ingelheim korea ltd acquired past experience products sales markets together business conditions boehringer ingelheim korea ltd indicates presents true fair view financial assets essentially include shareholder rights securities loans carried lower cost fair market value impaired current assets prepaid expenses inventories carried lower cost fair market value raw materials consumables supplies capitalised lower average acquisition prices fair market value balance sheet date finished goods work progress measured production cost basis individual calcula tions taking account directly attributable costs materials direct labour costs direct costs appropriate share production materials overheads depreciation goods resale valued lower either purchase cost fair market value identifiable risks inventory assets arising aboveaverage storage periods diminished marketability lower replacement costs taken account appropriate valuation adjustments annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements inventories valued lossfree ie deductions made expected sales prices reflect costs yet incurred receivables assets recognised cost less allowances specific risks general credit risk lowinterest noninterestbearing receivables term one year discounted securities classified current assets include securities recognised lower cost quotedmarket prices reporting date cash cash equivalents consisting cash balances banks cheques recognised lower cost fair market value deferred charges prepaid expenses recorded accordance section hgb include expenses paid advance certain period balance sheet date deferred charges recorded accordance section hgb include proceeds income certain period balance sheet date negative difference acquisition companies negative difference acquisition companies recognised following acquisitions march august value net assets acquired exceeded purchase prices paid value negative difference acquisition companies amounted eur million january increased acquisition company acquired august eur million amount release negative difference acqui sition companies line amortisation excess net assets recorded acquisition date period amortisation currently estimated ten years release negative difference acquisition companies eur million financial year eur million shown operating income group reserves group reserves include retained earnings consolidated subsidiaries prior years consolida tion entries affect earnings related previous years provisions tax provisions provisions include uncertain liabilities expected losses executory con tracts carried amount required settle obligation based reasonable business judge ment accordance prudence principle ie including future cost price increases provisions remaining term one year discounted using matchedterm average market interest rate last seven years accordance rckstellungsabzinsungsverordnung german regulation discounting provisions liabilities liabilities recognised settlement amount deferred taxes calculate deferred taxes arising temporary quasipermanent differences carrying amounts assets liabilities prepaid expenses deferred charges commercial balance sheet carrying amounts tax purposes tax loss carryforwards amounts resulting tax benefits expenses time differences reversed measured using tax rates specific respective consolidated company discounted differences due consolidation measures accordance sections hgb also measured using companyspecific tax rates time expected reversal difference deferred tax assets loss carryforwards taken account likely used within next five years deferred tax assets liabilities reported without netted annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements notes consolidated balance sheet intangible assets acquired concessions advance millions eur similar rights goodwill payments total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value tangible assets advance pay technical facili facilities mentsconst land buil ties machi operating ruction millions eur dings nes equipment progress total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated depreciation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements financial assets investments loans investments affiliated affiliated related investment millions eur companies companies companies securities loans total procurementmanufacturing costs balance currency conversion difference changes consolidated companies additions disposals reclassifications balance currency conversion difference changes consolidated companies additions disposals reclassifications balance accumulated amortisation balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance currency conversion difference changes consolidated companies additions writeups disposals reclassifications balance book value book value previous year loans item include loans shareholders inventories millions eur raw materials supplies unfinished products finished products goods resale advance payments suppliers accounts receivable assets residual residual term term millions eur year year trade accounts receivable receivables affiliated companies receivables related companies assets assets item includes receivables shareholders eur million previous year eur million receivables affiliated companies previous year almost exclusively consist receivables loans receivables related companies essentially consist trade accounts receivable provisions millions eur pension provisions tax provisions provisions annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements provisions pensions similar obligations provisions pensions similar obligations determined basis actuarial calculations using projected unit credit method taking account future adjustments salaries pensions addition local biometric data eg germany mortality tables g published prof dr klaus heubeck pension obligations significant countries calculated basis following actu arial parameters december germany usa japan discount rate salary increase pension increase provisions pensions similar obligations discounted using average market interest rate remaining term years accordance german regulation discounting provisions november interest rates used discount significant foreign pension obligations usa japan determined comparable parameters line german regulation discount ing provisions november plan assets intended solely cover pension similar obligations unavailable creditors cover assets defined section hgb measured fair market value essentially derived stock market prices offset underlying pension similar obligations fair market value plan assets balance sheet date eur million corresponding amount required settle offset pension obligations similar obligations eur million gains losses plan assets interest expense relating pension similar obligations offset accordance section hgb total eur million gains plan assets eur mil lion interest expense relating pension similar obligations included financial income liabilities residual term residual term less less millions eur year years years year bank loans accounts payable trade accounts payable advance payments accounts payable affiliated companies accounts payable related companies liabilities taxes eur million social security liabilities eur million previous year liabilities secured mortgages similar collateral rights balance sheet date end year liabilities shareholders eur million previous year eur million within item liabilities payables affiliated companies consist payables loans amounting eur million previous year eur million trade accounts payable amounting eur million previous year eur million annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements notes consolidated profit loss statement structure consolidated profit loss statement based total cost format net sales business business segment millions eur prescription medicines consumer health care animal health biopharmaceuticals industrial customers sales geographic region millions eur europe germany americas usa asia australia africa japan operating income operating income includes income currency translation eur million previous year eur million material costs millions eur costs raw material supplies goods resale expenditure services personnel costs millions eur salaries wages social benefits retirement benefits retirement benefits interest effects measurement provision pensions similar obligations shown separate item financial income average headcount production administration marketing sales research development apprentices amortisation intangible assets depreciation tangible assets amortisation intangible fixed assets depreciation fixed tangible assets include additional impairment writedowns previous year eur million operating expenses operating expenses include expenses currency translation eur million previous year eur million past operating expenses primarily include thirdparty services research development medicine marketing purposes administrative expenses fees contributions commissions rent freight expenses repairs carried third parties annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements financial result millions eur interest expense relating pensions similar obligations provisions interest expense similar expenditure interest expense similar expenditure amortisation loss disposal financial assets shortterm investments income investment securities longterm loans interest income similar proceeds holding income millions eur writeoffs financial assets income related companies affiliated companies taxes millions eur income taxes deferred taxes current income taxes essentially include corporation trade tax expense companies included consolidation result conclusion profit transfer agreements significant german corporations included trade corporation tax group parent company c h boehringer sohn ag co kg since january income taxes shareholders c h boehringer sohn ag co kg aris ing operating income reported consolidated profit loss statement trade income tax companies concerned fully consolidated german partnerships shown tax expenses total deferred tax assets amounted eur million balance sheet date deferred tax assets essentially relate different carrying amounts provisions fixed assets inventories deferred tax liabilities eur million recognised mainly relate differences carrying amounts tangible assets inventories provisions net income net income positively influenced operating income relating periods primarily reversal provisions eur million previous year eur million negatively influenced operating expenses relating periods eur million previous year eur million notes cash flow statement cash flow statement shows cash cash equivalents cash longterm securities invest ments classified current assets sold time boehringer ingelheim group changed result cash inflows outflows reporting year accordance german accounting standard cash flow statement gas cash flow statement broken according cash flows operating activities cash flows investing financing activities changes balance sheet items affiliated companies included translated using average rates year balance sheet cash cash equivalents carried closing rate effect exchange rate changes cash cash equivalents shown separately financial year interest eur million received interest eur million previous year eur million paid eur million previous year eur million paid taxes annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements disclosures contingent liabilities millions eur liabilities guarantees bills cheque guarantees warranties granting security thirdparty liabilities risk utilisation individual contingent liabilities estimated follows risk utilisation guarantees liabilities banks affiliated companies rated low account solid net assets financial position results operations subsidiaries question financial commitments balance sheet transactions millions eur rental leasing obligations purchase commitment obligations rental lease agreements eur million previous year eur million eur million previous year eur million relates longterm rental agreements sub sidiaries included consolidation purpose lease agreements lower capital commitment compared buying property absence resale risk risks could arise term lease longer possible fully utilise properties indications time financial commitments include future expenses followup investments investments already initiated future major repairs balance sheet date purchase commitments result future cash payments investments total eur million previous year eur million derivative financial instruments valuation units owing extensive international structure boehringer ingelheim group highly dependent developments worlds currencies interest rates hedge risks particularly emerging goods services financing currency forwards options generally used currency risks interest rate swaps options used interest rate risks use derivative financial instruments organisational processes set internal guide lines strict separation trading processing documentation control risk positions regularly tracked analysed measured special consolidated financial report positions entered periodically reevaluated monitored fair market values derivative financial instruments balance sheet date calculated using standard market measurement methods currency interest forwards using net present value method currency interest options using rec ognised option pricing models basis market data available balance sheet date currency interest options recognised fair market value exceeding option premium paid received derecognised maturity provisions eur million recognised currency forwards included hedge accounting negative fair market value within currency balance sheet date line imparity principle positive fair market values within currency recognised balance sheet date following derivative financial instruments included hedge accounting nominal value market value millions eur foreign exchange forward contracts requirements hedge accounting foreign exchange forward contracts highly probable fore casted transactions accordance section hgb met foreign exchange forward contracts recognised balance sheet line net hedge presentation method following accounting policies apply recognition hedges accordance section hgb economic hedges accounted hedge accounting hedges recognised per foreign currency net amount highly probable forecasted transactions currency forwards match forecasted net cash flow terms maturity nominal amount foreign currency macro hedge highly probable forecasted transactions incoming outgoing payments planned sales purchases derived company planning expost analysis planning shown planned transactions highly probable annual report boehringer ingelheim consolidated financial statements notes consolidated financial statements critical terms maturity nominal amount foreign currency match opposing changes value hedged item hedging instrument fully offset effective hedge therefore assumed prospectively retrospectively critical term match method exclusively used measure prospective retrospective effectiveness hedges december hedges highly probable forecast net cash flows recognised follows january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn gbp gbp gbp january december net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy gbp gbp gbp january february net cash flow millions eur fx forward contracts millions eur nominal value nominal value market value usd usd usd jpy jpy jpy amount hedged foreign currency risk correlates relative change exchange rate planning date realisation date forecasted transactions currencies appreciate depreciate euro would foreign currency risk plus minus eur mil lion without hedging balance sheet date one floatingrate loan amounting eur million interest rate swaps matching amounts matching maturities concluded hedge interest rate risk associated involves transforming floatingrate loan portions fixed interest rate use made hedge accounting micro hedges opposing changes value hedged item hedging instrument fully offset interest rate swaps including accrued interest negative fair market value eur million balance sheet date carrying amount equal deferred accrued interest eur million reported liabilities banks net hedge presentation method used research development expenses millions eur research development expenses research development expenses capitalised include costs phase iv clinical studies total auditor fees total fees charged group auditor financial year eur million eur million relates audits financial statements eur million services annual report boehringer ingelheim consolidated financial statements auditor report auditors report audited consolidated financial state conducted audit consolidated finan ments prepared ch boehringer sohn ag cial statements accordance article co kg ingelheim comprising balance sheet hgb german commercial code german income statement statement changes generally accepted standards audit equity cash flow statement notes financial statements promulgated institut consolidated financial statements together der wirtschaftsprfer institute public auditors group management report business germany idw standards require year january december plan perform audit misstate preparation consolidated financial state ments materially affecting presentation ments group management report net assets financial position results opera accordance german commercial law tions consolidated financial statements responsibility managing directors accordance german principles proper managing cor porate general partner responsi accounting group management report bility express opinion consolidated detected reasonable assurance knowl financial statements group management edge business activities economic report based audit legal environment group expecta tions possible misstatements taken account determination audit procedures effectiveness accountingrelated inter nal control system evidence supporting disclosures consolidated financial state ments group management report examined primarily test basis within framework audit audit includes assess ing annual financial statements compa nies included consolidation determination companies included consolidation accounting consolidation principles used significant estimates made managing directors managing corporate general part ner well evaluating overall presentation consolidated financial statements group management report believe audit provides reasonable basis opinion exception following qualification audit led reservations contrary article nos b hgb total remuneration granted members former members board managing directors members supervisory body well pension provisions recognized recognized former members board managing directors disclosed notes con solidated financial statements opinion based findings audit qualification mentioned con solidated financial statements comply legal requirements consolidated financial state ments give true fair view net assets financial position results operations group accordance german principles proper accounting group management report consistent consolidated financial statements comply legal requirements whole provides suitable view groups position suitably presents opportunities risks future development frankfurt main march pricewaterhousecoopers aktiengesellschaft wirtschaftsprfungsgesellschaft dr ulrich strk michael conrad wirtschaftsprfer wirtschaftsprfer german certified german certified public accountant public accountant annual report boehringer ingelheim product portfolio product portfolio selection branded prescription medicines consumer health care animal health annual report boehringer ingelheim product portfolio branded prescription medicines respiratory diseases chronic obstructive pulmonary disease copd bron bronchial asthma chial asthma among prevalent chronic dis bronchial asthma chronic inflammatory disorder eases affecting lungs frequent cause morbid airways chronic inflammation airways ity premature deaths worldwide accompanied airway hyperresponsiveness leads narrowing airways recurrent episodes idiopathic pulmonary fibrosis ipf rare disease wheezing breathlessness coughing particularly severely debilitating ultimately lethal night early hours morning known asthma triggered genetic envi copd ronmental factors eg allergens viral infections copd chronic disease lungs air quite variable breathing difficulties may occur ways become narrowed leads limitation air early stages disease airflow limitation flow causing shortness breath respiratory mally fully reversible patients free symp symptoms airflow limitation partially reversi toms attacks contrast copd asthma ble usually worsens gradually time destruction occur childhood lung tissue mainly affecting alveoli thus gas exchange excessive mucus airways inducing idiopathic pulmonary fibrosis ipf chronic cough contribute burden disease ipf chronic progressive severely debilitating complaints main reasons copd stress ultimately lethal lung disease limited ful patients lung emphysema chronic bronchitis treatment options ipf affects many people main manifestations copd per worldwide characterised progressive scarring lung tissue loss lung function time copd caused continuous damage lungs development scarred tissue called fibrosis time resulting inhaling pollutants primarily cigarette tissue thickens stiffens scarring lungs smoke also environmental pollutants air lose ability take transfer oxygen irritants lungs course copd bloodstream vital organs get enough oxygen disease occurs second half humans life result individuals ipf experience shortness characterised accelerated loss lung function breath nonproductive cough often difficulty compared normal ageing occasional sudden wors participating everyday physical activities ening symptoms function referred acute exacerbations indications brand names active ingredients chronic obstructive spiriva tiotropium bromide maintenance treatment patients pulmonary disease copd spiriva handihaler copd chronic obstructive pulmonary spiriva disease including chronic bronchitis emphysema maintenance treatment associated dyspnoea prevention exacerbations bronchial asthma spiriva respimat tiotropium bromide addon maintenance treatment adult patients asthma currently treated maintenance combination inhaled corticosteroids g budesonideday equivalent longacting agonists experienced one severe exacer bations previous year chronic obstructive striverdi respimat olodaterol maintenance treatment patients pulmonary disease copd chronic obstructive pulmonary disease copd bronchospasms associated combivent respimat ipratropium bromide combination short acting anticho reversible obstructive salbutamol linergic betaadrenergic airway diseases sulphate management reversible bronchos pasms associated obstructive air way diseases patients requiring one bronchodilator chronic obstructive atrovent ipratropium bromide treatment acute bronchospasm asso pulmonary disease copd ciated chronic obstructive pulmo chronic bronchitis nary disease copd including chronic bronchial asthma bronchitis asthma used con comitantly inhaled betaagonists treatment reversible airways obstruc tion acute chronic asthma used concomitantly inhaled betaagonists chronic obstructive airway berodual ipratropium bromide prevention treatment symptoms disorders bronchodual fenoterol chronic obstructive airway disorders duovent hydrobromide reversible airflow limitations bronchial asthma especially chronic bronchitis without emphysema bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attacks conditions versible airway narrowing eg chronic obstructive bronchitis prophylaxis exerciseinduced asthma annual report boehringer ingelheim product portfolio branded prescription medicines respiratory diseases continued cardiovascular diseases cardiovascular diseases leading causes death acute myocardial infarction many countries still increasing prevalence acute myocardial infarction heart attack acute event occurs thrombus clot suddenly stroke prevents blood flow area heart muscle unless stroke rapidly developing loss brain functions blood flow restored quickly affected section due reduced blood flow affected brain tissue heart muscle becomes permanently damaged heart attack due ischaemia lack blood supply caused leading cause death developed countries thrombosis embolism due bleeding result affected area brain unable function damage quickly becomes permanent untreated stroke acute event requiring emergency diagnosis intervention worldwide stroke one leading causes death longterm disability symptoms transient ischaemic attack tia similar stroke last minutes hours tia may precede stroke emergency medical care subsequent preven tive treatment necessary indications brand names active ingredients bronchial asthma alesion epinastine prophylactic treatment bronchial allergic rhinitis flurinol asthma prophylaxis symptomatic treatment allergic rhinitis idiopathic pulmonary fibrosis ofev nintedanib kinase inhibitor treatment ipf idiopathic pulmonary fibrosis ipf indications brand names active ingredients h ypertension micardis telmisartan treatment hypertension cardiovascular prevention micardisplus telmisartan hydrochlorothiazide reduction risk myocar micardis plus dial infarction heart attack stroke death cardiovascular cv causes micardishct patients years age older high comicardis risk developing major cv events unable take ace inhibitors usa reduction cardiovascular morbidity patients manifest atherothrombotic cardiovascular disease history coronary heart disease stroke peripheral arterial disease type diabetes mellitus documented target organ damage eu hypertension twynsta telmisartan amlodipine treatment hypertension alone micamlo antihypertensive agents initial micardis amlo therapy patients likely need multi ple antihypertensive agents achieve micardis duo blood pressure goals usa addon therapy adult patients adequately controlled blood pres sure amlodipine replacement therapy adult patients receiving tel misartan amlodipine separate tablets eu annual report boehringer ingelheim product portfolio branded prescription medicines cardiovascular diseases continued hypertension cardiovascular diseases atrial fibrillation hypertension also referred high blood pressure patients atrial fibrillation af higher risk chronic disease blood pressure chronically developing blood clots cause disabling stroke elevated hypertension one major risk factors clots travel brain af common type strokes heart attacks heart failure chronic renal failure arrhythmia associated hypercoagul able state predisposes stroke systemic embolism one billion people worldwide affected prevented effective chronic anticoagulation hypertension prevalence hypertension increases steadily age world population ageing prevention venous thromboembolism preventive strategies terms lifestyle changes patients undergoing orthopaedic surgery consider far failing prevalence hypertension set able risk developing deep vein thrombosis legs increase even potentially fatal pulmonary embolism also known venous thromboembolism vte longer hypertension major risk factor cardiovascular term thromboembolic events may recur chronic morbidity mortality organs risk primarily venous insufficiency andor pulmonary hypertension may heart main blood vessels brain kidneys occur prevent vte events consequences pa primary goal antihypertensive treatment tients receive kind thromboprophylaxis prevent cardiovascular events heart attacks strokes finally reduce cardiovascular mortality treatment venous thromboembolism cardiovascular disease cvd responsible nearly one vte umbrella term encompasses deep vein three deaths worldwide number one cause thrombosis dvt pulmonary embolism pe dvt death process occurs thrombus blood clot forms deep vein commonly calf leg par proper control treatable risk factors disease tially completely blocks flow blood one vital prevention cardiovascular events major contributing factors dvt pathogenesis venous stasis thrombus grows portion may break away main clot travel circulatory system lungs lodging blood clot arteries lung called pe vte serious disorder poten tially fatal consequences patients already suffer vte require anticoagulant treatment secondary prevention recurrent thromboembolic event indications brand names active ingredients secondary prevention aggrenox dipyridamole prevention stroke following first stroke transient ischaemic asasantin acetylsalicylic acid stroke transient ischaemic attacks attacks tia asasantin retard h ypertension catapresan clonidine treatment hypertension catapres hydrochloride clonidine catapressan cataprestts dixarit acute ischaemic stroke actilyse alteplase fibrinolytic treatment acute ischae acute myocardial infarction actilyse cathflo mic stroke acute myocardial infarction acute massive pulmonary acute massive pulmonary embolism embolism catheter clearance due thrombotic catheter clearance due occlusion thrombotic occlusion acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocar dial infarction hypertension motens lacidipine treatment hypertension stroke prevention atrial pradaxa dabigatran etexilate prevention strokes blood clots fibrillation pradaxar patients abnormal heart rhythm primary prevention venous prazaxa atrial fibrillation thromboembolic events primary prevention venous thrombo orthopaedic surgery embolic events vte adults treatment secondary elective total hip knee replacement prevention venous throm surgery boembolic events treatment deep vein thrombosis dvt pulmonary embolism pe secondary prevention recurrent dvt pe adults annual report boehringer ingelheim product portfolio prescription medicines metabolic diseases diabetes type diabetes chronic progressive condition tion management estimated number cause longterm complications well controlled cases reach million every year million deaths worldwide linked directly longterm complications diabetes include nephropathy longterm effects diabetes type diabetes leading renal failure potential risk dialysis common form accounts retinopathy potential loss vision increased cases developed world affects million incidence stroke cardiovascular diseases periph people worldwide imposing enormous burden eral neuropathy risk foot ulcers foot health care systems globally without effective preven leg amputations autonomic neuropathy causing gas trointestinal genitourinary cardiovascular symptoms sexual dysfunction oncology cancer threat global health estimated lung cancer one disease differ million new cases cancer diagnosed world ent subtypes small cell lung cancer sclc wide million people died malignant nonsmall cell lung cancer nsclc differ disease common newly diagnosed cancer types ent molecular genetic aberrations mutations present lung cancer breast cancer colorectal tumour identified focusing molecular cancer changes specific specific subtype lung cancer targeted therapies may effective lung cancer treatments less harmful normal cells thereby reduc lung cancer bronchogenic carcinoma refers malig ing side effects normal cells nant abnormal cell growth inside lung tissue forming cluster tumour common cancer estimated million new cases per year worldwide smoking primary cause disease contributing cases recently incidence lung cancer among nonsmokers women increased lung cer negative prognosis million deaths per year representing cancer deaths lung cancer signs unspecific may take many years appear late diagnosis advanced stage disease results negative prognosis lung cancer patients surviving five years following diagnosis indications brand names active ingredients type diabetes mellitus trajenta linagliptin treatment type diabetes mellitus tradjenta improve glycaemic control adults trazenta used monotherapy metformin tolerated contraindicated trayenta combination therapy type diabetes mellitus jentadueto linagliptin metformin hydrochloride treatment type diabetes mellitus trayenta duo improve glycaemic control adults trajenta duo treatment metformin lead sufficient control trajentamet patients treated trajenta metformin type diabetes mellitus jardiance empagliflozin treatment type diabetes mellitus jardianz improve glycaemic control adults used monotherapy diet exercise alone provide adequate glycaemic control metformin considered inappropriate due intoler ance combination therapy indications brand names active ingredients nonsmall cell lung cancer giotrif afatinib treatment patients nsclc gilotrif metastatic nonsmall cell lung cancer nsclc whose tumors activating epidermal growth factor receptor egfr mutations nonsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patients locally advanced metastatic locally nonsmall cell lung cancer nsclc adenocarcinoma tumour histology firstline chemotherapy annual report boehringer ingelheim product portfolio branded prescription medicines diseases central nervous system mental neurological diseases depression restless legs syndrome rls parkinsons disease significantly impact patients restless legs syndrome rls common neurological families substantial burden society disorder characterised uncontrollable urge move legs primarily occurring evening night parkinsons disease hours usually accompanied unpleasant parkinsons disease pd degenerative disorder times painful sensations legs well disturbed central nervous system patients usually notice motor sleep resulting daytime tiredness sleepiness symptoms like hand tremor shaking first sign sensations felt deep within legs described disease progresses eventually include shaking creeping crawling aching arms legs head motor symptoms may develop time include stiffness often results loss facial expression gradual slowing loss motion freezing patients also suffer nonmotor symptoms associated pd dementia depression sleep disorders primary symptoms result lack neurotransmitter dopamine distinct areas human brain infectious diseases hiv infectionaids acquired immune deficiency syndrome aids set symptoms infections resulting damage human immune system caused human immu nodeficiency virus hiv untreated condition pro gressively reduces effectiveness immune system leaves individuals susceptible opportunistic infec tions tumours babies infected mothers risk getting virus pregnancy childbirth breastfeeding indications brand names active ingredients parkinsons disease pd sifrol pramipexole symptomatic treatment idiopathic restless legs syndrome rls mirapex parkinsons disease may used mirapexin monotherapy combination levodopa symptomatic treatment pexola idiopathic moderate severe restless legs syndrome sleep disorders lendormin brotizolam shortterm treatment disorders lindormin initiating maintaining sleep insomnia requiring pharmacological intervention indications brand names active ingredients hivaids viramune nevirapine combination therapy hiv viramune xr infection several countries prevention mothertochild trans mission hiv pregnant women taking antiretroviral therapy time labour prolonged release tablets oncedaily dosing within combination therapy hivaids aptivus tipranavir indicated combination antiretroviral treatment hivinfected patients coadministered mg ritona vir treatmentexperienced infected hiv strains resistant one protease inhibitor annual report boehringer ingelheim product portfolio consumer health care cough cold mucosolvan ambroxol bisolvon bromhexine bisolvon market since bromhex indicated secretolytic therapy broncho ine contained various formulations bisolvon pulmonary diseases associated abnormal mucus shown increase proportion serious secretion impaired mucus transport bronchial secretion making easily expectorated bromhexine also enhances mucus transport reducing cough common symptom clinical impor mucus viscosity activating ciliated epithelium tance frequent reason consulting doctor visiting pharmacy clinical symptoms cough dextromethorphan symptomatic treatment expectoration led development drugs irritable nonproductive cough marketed vari affect respiratory mucus ie mucoactive agents ety tradenames specific countries mucosolvan promotes mucus clearance facili mucoviral bisolviral antiviral nasal sprays tates expectoration eases productive cough allowing launched sprays contain iotacarrageenan patients breathe freely deeply available many extracted natural red seaweed different product forms formulations typically applied nasally iotacarrageenan acts like protective based active igredient ambroxol layer physically inhibits infection nasal epithe lial cells cold viruses since viruses dock ambroxol active metabolite bromhexine specific receptors cell surface clinical trials synthetic derivative herbal active ingredient use mucoviralbisolviral shown vasicine extracted plant species adhatoda vasica duce viral load patients nasal secretion ambroxol mucoactive drug several properties relieve symptoms cold including secretolytic secretomotoric actions restore physiological clearance mechanisms respiratory boxagrippal launched germany follow tract play important role bodys natural ing successful switch prescription overthe defence mechanisms ambroxol also stimulates synthesis counter otc medicine status cold remedy combines release surfactant type ii pneumocytes antiinflammatory pain reliever nsaid ibuprofen oral decongestant pseudoephedrine hydrochlo ride treat troublesome symptoms cold blocked nose sinuses combination headache fever coldrelated pain indications brand names active ingredients acute chronic broncho mucosolvan ambroxol secretolytic therapy acute chronic pulmonary diseases mucosan bronchopulmonary diseases associated surbronc abnormal mucus secretion impaired mucus transport lasolvan mucopect acute chronic broncho bisolvon bromhexine secretolytic therapy acute chronic pulmonary diseases bronchopulmonary diseases associated abnormal mucus secretion impaired mucus transport irritable cough silomat dmp dextromethorphan symptomatic treatment irritable bisoltussin nonproductive cough bisolvon dry bisolsek bisolvon antitusivo mugotussol mucotussin common cold mucoviral iotacarrageenan antiviral treatment common cold bisolviral also used sustained moisturi surbroncviral sation nasal mucosa common cold boxagrippal ibuprofen symptomatic treatment nasal conges bisolfren pseudoephedrine tion combination headache fever annual report boehringer ingelheim product portfolio consumer health care sore throat main brands tratment sore throat addition secretolytic activity ambroxol potent mucoangin lysopaine inhibitor neuronal sodium channels therefore mucoangin shown local anaesthetic effect mucoangin ambroxol indicated pain relief described first late explained acute sore throat pain sore throat hallmark confirmed recent work acute pharyngitis usually caused viral infection infection rule selflimiting patient lysopaine cetylpyridinium local adjuvant antibac mally recovers couple days bother terial treatment indicated limited infections patient continuous pain throat buccal oropharynx mucosa mild sore throat maximised swallowing main goal aphtae small oral wounds treatment thus reduce pain pain brand thomapyrin comprises products migraines thomapyrin positioned expert treatment acute pain mild moderate intensity treatment headaches several line extensions available thomapyrin classic normal headache thomapyrin classic core product com thomapyrin intensiv stronger headache posed triple combination acetylsalicylic acid pa thomapyrin effervescent tablets galenic alter native racetamol caffeine three components suppress pain synergistically via interaction several pain alongside thomapyrin boehringer ingelheim also offers related molecular mechanisms result thomapyrin analgesics combination ibuprofen allylisopropylac classic offers faster superior efficacy compared etylurea dehydrated caffeine magnesium oxide single components proven japan tradename eve mono active stateoftheart clinical studies ingredient metamizole brazil tradename anador reason triple combination recommended many national international medical societies another brand finalgonnonivamid nicoboxil first choice acute treatment tensiontype headaches topical cream joint muscle pains indications brand names active ingredients sore throat mucoangin ambroxol pain relief acute sore throat lysopadol lysopain dol isodinemint zerinol gola sore throat lysopaine cetylpyridinium pain relief sore throat indications brand names active ingredients pain thomapyrin acetylsalicylic acid adults adolescents older thomapyrin paracetamol caffeine years acute treatment mild classic moderate headache migraine attacks thomapyrin without aura treat intensiv ment tensiontype headache available germany pain eve ibuprofen adults older years reduc eve allylisopropylacetylurea dehydrated tion fever temporary relief mild eve quick caffeine magnesium oxide moderate aches pains associated headache menstrual pain body pains available japan eve quick pain anador metamizole adults adolescents older lisalgil years acute treatment mild nolotil moderate headache prodolina available brazil pain finalgon salbe nonivamid nicoboxil stimulate blood flow skin finalgon wrme thick extract treating joint muscle complaints creme stark chili pepper finalgon cpd wrmecreme available germany finalgon cpd wrmecreme annual report boehringer ingelheim product portfolio consumer health care gastrointestinal diseases gastrointestinal portfolio offer several brands buscopan antispasmodic product active dulcolax surulac laxoberal guttalax ingredient hyoscine butylbromide product derived buscopan well heartburn brands zantac scopolamine hyoscine natural substance ex buscopan antiacido gastol tracted duboisia plant species chemically modi fied quaternary ammonium compound hyoscine constipation common problem dulcolax butylbromide antispasmodic product buscopan acts leading overthecounter otc laxative remedy con directly site abdominal pain relaxing stipation relief worldwide smooth muscles gastrointestinal biliary urinary genital tracts dulcolax tablets special enteric comfort coating ensures active ingredient means buscopan relieves abdominal pain dulcolax tablets bisacodyl taken needs directly treating main cause abdominal cramp act colon colon colonic juices spasm activate key ingredient relieves consti pation stimulates natural movement bowels today buscopan available several line extensions provide gentle predictable relief within hours mono variant different combinations anal one two tablets taken going bed provide gesics paracetamol ibuprofen metamizoledipyrone relief next morning different formulations tablets drops suppositories syrup solutions intravenous injection products within dulcolax range include dulcoease dulcoenema dulcogas umbrella brand buscopan also offers buscofem menstrual pain relief well buscopan antiacido surulac constipation brand japan buscopan reflusso heartburn relief consumers offered surulac laxative tablet laxoberal guttalax brands offering extended gastrointestinal portfolio consumers constipation relief flexible dosage vaprino selfmedication product diarrhoea format namely drops active ingredient racecadotril effective various forms acute diarrhoea reducing excessive secretion abdominal cramping pain discomfort common gut without changing gastrointestinal transit ailments approximately one four persons worldwide time motility vaprino provides new suffers regular basis mode action enables fast relief diarrhoea without blocking bowels indications brand names active ingredients constipation dulcolax bisacodyl laxative use patients suffering surulac bisacodyl sennoside constipation preparation diagnostic procedures pre postoperative treatment condi tions require defecation facili tated constipation laxoberal sodium picosulphate laxative use cases constipation laxoberon conditions require defeca guttalax tion facilitated dulcolax np gas bloating dulcogas simethicone fastacting granules relieve gas bloating prevent flatulence abdominal pain buscopan hyoscine butylbromide treatment relief abdominal buscapina hyoscine butylbromide paracetamol cramping pain discomfort buscopan plus buscapina plus heartburn zantac ranitidine relieves heartburn associated acid buscopan antiacido indigestion sour stomach prevents heartburn associated acid indiges tion sour stomach brought certain foods beverages available usa acute diarrhoea vaprino racecadotril treatment symptoms acute diar rhoea adults annual report boehringer ingelheim product portfolio consumer health care vitamins supplements pharmaton multivitamin mineral supplements pharmaton kiddi range products designed brand developed support physical mental well children contains selected vitamins minerals full range products adapted needs essential amino acid lysine important different target audiences developed work period growth also recommended pre harmony body ventive treatment vitamin deficiencies pharmaton vitality range products adults pharmaton matruelle indicated women contains selected blend vitamins minerals trace actively planning get pregnant pregnant women elements plus standardised ginseng extract g breastfeeding women contains important main target indications exhaustion tiredness micronutrients mother baby vitamins decreasing concentration mental alertness well minerals omega fatty acids cover increased cases deficient nutrition loss appetite debility due needs substances particular periods illness convalescence numerous clinical studies moreover helps protect embryonal neural shown regular intake pharmaton tube diseases foetus iron folic acid positive effect mental physical performance anaemia pregnancy breastfeeding wellbeing indications brand names active ingredients tiredness decreasing concen pharmaton standardised ginseng improve general wellbeing tration cases deficient pharmaton vitality extract vitamins nutrition loss appetite pharmaton geriavit minerals trace debility due illness elements geriatric pharmaton convalescence gericomplex pharmaton complex pharmaton fizzi pharmaton active life increased demand vita pharmaton kiddi vitamins increased demand vitamins minerals mins childhood minerals amino acids especially amino acids period growth preventive treatment cases vitamin deficiencies eg restricted diets convalescence loss appetite following illness infection surgery prophylaxis iron folic pharmaton matruelle vitamins minerals women pregnancy acid deficiency preg trace elements preventing deficiency symptoms nancy omega fatty acids covering increased needs vita docosahexaenoic mins minerals trace elements dha acid dha provide protection embryonal neural tube diseases foetus prophylaxis iron folic acid anae mia pregnancy breastfeeding annual report boehringer ingelheim product portfolio consumer health care leg vein health brand name antistax boehringer ingelheim treatment described symptoms antistax helps markets range products developed prevention keep fluid flows small venous vessels treatment symptoms attributable chronic venous venules surrounding tissue normal levels insufficiency common symptoms venous even standing sitting long time insufficiency observable consumers varicose veins oedema lower leg heavy tired legs sensation red vine leaf extract active ingredient antistax tension tingling cramps pain antistax capsules products antiinflammatory effect works tablets scientifically proven help maintain endothelium inside venules sealing healthy leg vein circulation inside thereby reducing swelling sensa tion pain heaviness heavy aching tired legs often occur long periods standing sitting increase end day products available antistax range include summer outdoor temperatures rise antistax tablets antistaxcapsules antistax antistax tablets antistax capsules offer effective creme well cosmetic product antistax leg chilling gel urological diseases benign prostate hyperplasia bph refers enlargement prostate middleaged elderly men lead lower urinary tract symptoms luts fre quent nighttime urination urge urinate every hours weak flow feeling unfinished urinating indications brand names active ingredients chronic venous insufficiency antistax red vine leaf extract prevention treatment symptoms chronic venous insufficiency varicose veins leg oedema painful swollen legs tingling legs tired heavy legs heavy tired legs antistax cooling caring symptomatic treatment heavy tired substances red vine legs leaf extract indications brand names active ingredients benign prostate hyperplasia flomax relief tamsulosin treatment lower urinary tract symp bph toms luts common condition called benign prostate hyperplasia bph available uk overthecounter otc medication annual report boehringer ingelheim product portfolio animal health foodproducing animals swine infectious respiratory diseases ingelvac mycoflex licensed active immunisa ingelvac circoflex first singledose piglet vac tion pigs enzootic pneumonia ep single cine control porcine circovirus disease pcvd dose regimen advanced adjuvant system vaccine provides significant reduction mortality provides longlasting effective protection proven acute phase pcvd well improved growth rates even highchallenge situations chronic phase disease ingelvac circoflex protects minimal systemic adverse reactions injec infectious enteric diseases tion site swellings ingelvac prrs mlv licensed ac enterisol ileitis first vaccine tive immunisation respiratory reproductive ileitis caused lawsonia intracellularis licensed form porcine reproductive respiratory syndrome improve weight gain reduce growth variability prrs associated disease enterisol ileitis helps reduce total antimicrobial use pork production foodproducing animals poultry volvac umbrella brand boehringer ingel influenza infectious bronchitis newcastle disease infec heim animal health poultry vaccine range consists tious bursal disease egg drop syndrome avian coryza wide range live inactivated vaccines broilers volvac vaccines also allow birds express layers vaccines provide protection birds full potential increase wellbeing various viral bacterial diseases like avian indica tions brand names active ingredients infectious respiratory ingelvac circoflex recombinant vaccine active immunisation pigs iseases porcine circovirus age two weeks porcine type pcv circovirus type reduce mortality clinical signs including weight loss lesions lymphoid tissues asso ciated porcine circovirus diseases pcvd addition vaccination shown reduce pcv nasal shedding viral load blood lymphoid tissues duration viraemia infectious respiratory ingelvac prrs mlv attenuated live vaccine active immunisation swine iseases prrs virus age three weeks respiratory reproductive form prrs virus infection porcine reproduc tive respiratory syndrome infectious respiratory ingelvac mycoflex inactivated vaccine active immunisation pigs iseases mycoplasma age three weeks lung hyopneumoniae lesions following infections myco plasma hyopneumoniae infectious enteric diseases enterisol ileitis attenuated live active immunisation pigs vaccine lawsonia age three weeks intestinal intracellularis lesions caused lawsonia intracellula ris infection reduce growth varia bility loss weight gain associated disease indica tions brand names active ingredients various viral bacterial volvac polyvalent attenuated live vaccination healthy chickens diseases poultry inactivated vaccine diseases caused included containing antigens antigens common diseases vaccination avian responsible losses egg production influenza newcastle disease layers affecting health avian coryza egg drop broiler chickens syndrome infectious bronchitis infectious bursal disease bacterium anatis annual report boehringer ingelheim product portfolio animal health foodproducing animals cattle mastitis mastitis inflammation udder dairy cattle mainly caused bacterial infection prevention treatment mastitis animals key producing healthy milk minimising symptoms associated clinical situation ubrolexin today two products treatment acute bacterial mastitis whereas ubrostar tomorrow used prevent mastitis dryingoff dairy cattle end lactation period mamyzin effective injectable antimicrobial treatment acute mastitis metacam used reduce acute pain associated syndrome indica tions brand names active ingredients astitis mamyzin penethamate hydroiodide treatment mastitis dairy cows astitis benestermycin penethamate hydroiodide treatment subclinical mammary ubrostar framycetin sulphate fections present dryingoff b enethamine penicillin astitis ubrolexin cefalexin monohydrate treatment clinical mastitis lactating kanamycin monosulphate dairy cows caused bacteria astitis today cephapirin sodium intramammary infusion lactat ing cows us astitis tomorrow cephapirin benzathine intramammary infusion dry cow us annual report boehringer ingelheim product portfolio animal health foodproducing animals cattle continued pain inflammatory diseases metacam member class nonsteroidal metacam licensed use cattle suffering antiinflammatory drugs nsaid addresses need respiratory disease also indicated calves affected maintained profitability concern animal diarrhoea adjunctive therapy treatment welfare animal production due longacting mastitis lactating cows nature outstanding efficacy controlling flammatory symptoms helps minimise losses bovine viral diarrhoea virus bvdv one major inflammation maintain profitability animals economically important cattle pathogens world suffering disease time metacam wide distribution disease caused bvdv results effectively controls pain supports restoration marked production losses dairy beef herds wellbeing farm animals use metacam bovela vaccine designed reduce convenient inflicts minimal stress animals due clinical signs typical bvd prevent birth lowvolume oneshot dosage socalled persistently infected animals caused trans placental infection bvdv vaccination bovela expected provide protection within herd disease circulation virus indica tions brand names active ingredients pain inflammatory metacam meloxicam alleviation inflammation pain iseases muscoloskeletal disorders dog cat pigs horse surgery dog cat pigs colic horse adjunctive treatment diarrhoea respiratory disease acute mastitis dehorning cattle well masti tismetritisagalactia syndrome pigs cattle infectious diseases pyramid attenuated vaccine bovine vaccination healthy dairy beef presponse rhinotracheitisvirus diarrhoea cattle aid prevention diseases parainfluenza respiratory syncytial caused included antigens us virus mannheimia haemolytica canada toxoid bovine viral diarrhoea bovela modified live bvdv strain modi active immunisation cattle fied live bvdv strain three months age reduce hyper thermia minimise reduction leukocyte count caused bovine viral diarrhoea virus bvdv bvdv reduce virus shedding viraemia caused bvdv active immunisation cattle bvdv bvdv prevent birth persistently infected calves caused bovine viral diarrhoea virus transplacental infection annual report boehringer ingelheim product portfolio animal health companion animals horse main horse products focus therapeutic areas lack dopamine pituitary pars intermedia clinical signs respiratory disease lameness colic hormonal disorders hypertrichiosis laminitis change body conformation lack performance treatment prascend lifelong ventipulmin treatment acute chronic respi ratory disease airway obstruction due bron vetera vaccines first vaccine portfolio include chospasm andor mucus accumulation contributing multiple convenient combinations disease protection factor improved mucociliary clearance desirable horses young four months age vaccines protect ventipulmin used alone adjunctive therapy many nine infectious organisms including influ chronic obstructive pulmonary disease copd enza herpes west nile virus tetanus others en acute subacute chronic respiratory allergic conditions ables customised protection horse limited needle injections vetera vaccines formulated utilising prascend indicated treatment pituitary pars ultrafil purification technology removing extraneous intermedia dysfunction ppid also known proteins allowing horses immune system focus equine cushings disease prascend substitutes relevant antigens indica tions brand names active ingredients acute chronic obstructive ventipulmin clenbuterol respiratory diseases attended bron respiratory diseases chial spasms like subacute chronic bronchitis bronchiolitis chronic obstructive pulmonary disease copd auxillary acute bronchitis pneumonia bronchia pituitary pars intermedia prascend pergolide mesylate treatment clinical signs asso dysfunction ppid ciated pituitary pars intermedia dysfunction ppid also known equine cushings disease way combination vetera eastern western venezuelan vaccination healthy horses vaccines common encephalomyelitis tetanus aid prevention diseases caused diseases horses west nile virus included antigens us canada equine herpes virus equine influenza viruses annual report boehringer ingelheim product portfolio animal health companion animals small animals main small animal products address major chronic prozinc aqueous protamine zinc pzi suspension diseases heart failure kidney disease epilepsy osteo recombinant human insulin used reduce arthritis hyperglycaemia cats diabetes mellitus first new class heart treatments termed semintra angiotensin ii antagonist odilators vetmedin shown significantly approved reduction proteinuria associated improve clinical signs extend life expectancy dogs chronic kidney disease ckd cats semintra de congestive heart failure origin ating dilated creases mean arterial blood pressure proteinuria cardiomyopathy valvular insufficiency mitral andor available oral solution tricuspid regurgitation vetmedin works two complementary modes action opens blood pexion alternative treatment canine epilepsy vessels taking blood away heart thereby active substances imepitoin primarily inhibits seizures via lowering pressure heart reducing work potentiation gabaareceptormediated inhibitory heart pump blood around dogs body effects neurons pexion approved reduction time vetmedin direct effect generalised seizures due idiopathic epilepsy heart muscle helping beat stronger pump blood potential safety benefits existing standard treatment efficiently duramune vaccine designed aid prevention metacam nonsteroidal antiinflammatory drug wide spectrum common infectious diseases nsaid available oral suspension tablets dogs diseases serious injectable solution dogs oral suspension cases even fatal effective prevention including appro injectable solution cats dogs indications priate vaccination reduces impact diseases include alleviation inflammation pain dogs acute chronic musculoskeletal disorders well reduction postoperative pain following surgery cats indications include alleviation inflamma tion pain acute chronic musculoskeletal dis orders well alleviation mild moderate post operative pain following surgical procedures variety formulations offers veterinarians owners flexi bility use formulations prefer manage various levels inflammation pain associated licensed indications indica tions brand names active ingredients congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originated dilatative cardio myophathy valvular insufficiency mitral andor tricuspid regurgitation pain inflammatory metacam meloxicam dogs indications include iseases alleviation inflammation pain acute chronic musculoskeletal disorders well reduction postoperative pain following surgery cats indications include alleviation inflammation pain acute chronic musculoskeletal disorders well alleviation mild moderate postoperative pain following surgical procedures feline diabetes mellitus prozinc protamine zinc reduction hyperglycaemia recombinant hyperglycaemiaassociated clinical signs human insulin cats diabetes mellitus feline chronic kidney disease semintra telmisartan reduction proteinuria associated chronic kidney disease ckd cats canine idiopathic epilepsy pexion imepitoin reduction frequency generalised seizures due idiopathic epilepsy dogs careful evaluation alternative treatment options canine infectious diseases duramune inactivated attenuated vaccine vaccination healthy dogs aid canine distemper canine prevention diseases caused adenovirus type coronavirus included antigens us canada parainfluenzavirus parvovirus borrelia australia burgdorferi leptospira canicola grippotyphosaicterohaemorrhagiae pomona annual report boehringer ingelheim imprint queries comments please hesitate contact us boehringer ingelheim gmbh binger strae ingelheim germany telephone fax contact corporate division communications email webmasterboehringeringelheimcom internet wwwboehringeringelheimcom issued boehringer ingelheim gmbh concept design layout mpm corporate communication solutions wwwdigitalagenturmpmde photos fotolia p lennart nilsson p getty images p science photo p masahiko uchiyama p jonathan kannair jonathankannaircom p stewart turkington p dieth schrder fotografie p secundino paulino boehringer ingelheim pharmaceuticals inc p printed sddeutsche verlagsgesellschaft ulm copyright boehringer ingelheim gmbh rights reserved part annual report may reproduced transmitted form means electronic photocopy without permission writing boehringer ingelheim gmbh figures third parties used annual report based data available time financial statement drawn co emission reduction certificates support project distri butes water treatment units households rural districts kenya project improves public health significantly inasmuch guarantees access clean drinking water c h boehringer sohn ag co kg ingelheim comparison balance sheets millions eur comparison balance sheets financial data assets december intangible assets tangible assets financial assets fixed assets inventories accounts receivable incl deferred charges deferred taxes liquid funds current assets incl deffered charges deferred taxes total assets liabilities equity december shareholders capital reserves incl currency conversion difference net income total equity minority interests group equity negative difference acquisition companies provisions incl deferred taxes liabilities incl deferred charges total liabilities incl deferred taxes deferred charges total liabilities equity summary selected financial data net sales operating income operating income net sales income taxes income taxes net sales return shareholders equity equity ratio cash flow financial funds personnel costs personnel costs net sales average number employees research development costs r net sales investments tangible assets depreciation tangible assets wwwboehringeringelheimcom annualreportboehringeringelheimcom